Publikationen

2023

Aldin A, Besiroglu B, Adams A, Monsef I, Piechotta V, Tomlinson E, Hornbach C, Dressen N, Goldkuhle M, Maisch P, Dahm P, Heidenreich A, Skoetz N. First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2023 May 4;5(5):CD013798.

Bolenz C, Kunath F, Zengerling F, Wezel F, Schmidt S, Hartmann A, Eckstein M. Increasing Biomarker Guidance in the Treatment of Urothelial Carcinoma: Systematic Review of International Clinical Trials. Urol Int. 2023;107(5):480-488.

Bolenz C, Zengerling F. Urologie. [Neoadjuvant chemotherapy in patients with high-risk upper tract urothelial carcinoma: current evidence]. 2023 May;62(5):522-524.

Breyer J, Eckstein M, Sikic D, Wezel F, Roghmann F, Brehmer M, Wirtz RM, Jarczyk J, Erben P, Bahlinger V, Goldschmidt F, Fechner G, Chen J, Paxinos E, Bates M, Haas M, Zengerling F, Bolenz C, Burger M, Hartmann A, Kriegmair MC; BRIDGE Consortium e.V. Xpert bladder cancer monitor to predict the need for a second TURB (MoniTURB trial). Sci Rep. 2023 Sep 18;13(1):15437.

Cox A, Klümper N, Stein J, Sikic D, Breyer J, Bolenz C, Roghmann F, Erben P, Wirtz RM, Wullich B, Ritter M, Hölzel M, Schwamborn K, Horn T, Gschwend J, Hartmann A, Weichert W, Erlmeier F, Eckstein M. Molecular Urothelial Tumor Cell Subtypes Remain Stable During Metastatic Evolution. Eur Urol. 2023 Apr 6:S0302-2838(23)02698-2.

Erlmeier F, Klümper N, Landgraf L, Strissel PL, Strick R, Sikic D, Taubert H, Wach S, Geppert CI, Bahlinger V, Breyer J, Ritter M, Bolenz C, Roghmann F, Erben P, Schwamborn K, Wirtz RM, Horn T, Wullich B, Hölzel M, Hartmann A, Gschwend JE, Weichert W, Eckstein M. Spatial Immunephenotypes of Distant Metastases but not Matched Primary Urothelial Carcinomas Predict Response to Immune Checkpoint Inhibition. Eur Urol. 2023 Feb;83(2):133-142.

Grimm MO, Grün CB, Niegisch G, Pichler M, Roghmann F, Schmitz-Dräger B, Baretton G, Schmitz M, Bolenz C, Foller S, Leucht K, Schumacher U, Schostak M, Meran J, Loidl W, Zengerling F. Tailored immunotherapy approach with nivolumab with or without ipilimumab in patients with advanced transitional cell carcinoma after platinum-based chemotherapy (TITAN-TCC): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2023 Apr;24(4):347-359.

Heinzelbecker J, Spieler N, Kuehn M, Fischer C, Volkmer B, von Rundstedt F, Albers P, Becht E, Bannowsky A, Weber HM, Hofmann R, Müller M, Langbein S, Steiner G, Retz M, Kamradt J, Wagenpfeil G, Wellek S, Lehmann J, Stoeckle M. Adjuvant vs. progression-triggered treatment with gemcitabine in platinum-ineligible high-risk bladder cancer patients: Long-term follow-up of a randomized phase 3 trial. Urol Oncol. 2023 Aug;41(8):356.e19-356.e30.

Hoeh B, Garcia CC, Banek S, Klümper N, Cox A, Ellinger J, Schmucker P, Hahn O, Mattigk A, Zengerling F, Becker P, Erdmann K, Buerk BT, Flegar L, Huber J, Kalogirou C, Zeuschner P. Early CRP kinetics to predict long-term efficacy of first-line immune-checkpoint inhibition combination therapies in metastatic renal cell carcinoma: an updated multicentre real-world experience applying different CRP kinetics definitions. Clin Transl Immunology. 2023 Oct 25;12(10):e1471.

Klümper N, Ralser DJ, Ellinger J, Roghmann F, Albrecht J, Below E, Alajati A, Sikic D, Breyer J, Bolenz C, Zengerling F, Erben P, Schwamborn K, Wirtz RM, Horn T, Nagy D, Toma M, Kristiansen G, Büttner T, Hahn O, Grünwald V, Darr C, Erne E, Rausch S, Bedke J, Schlack K, Abbas M, Zschäbitz S, Schwab C, Mustea A, Adam P, Manseck A, Wullich B, Ritter M, Hartmann A, Gschwend J, Weichert W, Erlmeier F, Hölzel M, Eckstein M. Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance. Clin Cancer Res. 2023 Apr 14;29(8):1496-1505.

Klümper N, Wüst L, Saal J, Ralser DJ, Zarbl R, Jarczyk J, Breyer J, Sikic D, Wullich B, Bolenz C, Roghmann F, Hölzel M, Ritter M, Strieth S, Hartmann A, Erben P, Wirtz RM, Landsberg J, Dietrich D, Eckstein M. PD-L1 (CD274) promoter hypomethylation predicts immunotherapy response in metastatic urothelial carcinoma. Oncoimmunology. 2023 Oct 19;12(1):2267744.

Köllges R, Stegmann J, Schneider S, Waffenschmidt L, Fazaal J, Breuer K, Hilger AC, Dworschak GC, Mingardo E, Rösch W, Hofmann A, Neissner C, Ebert AK, Stein R, Younsi N, Hirsch-Koch K, Schmiedeke E, Zwink N, Jenetzky E, Thiele H, Ludwig KU, Reutter H. Exome Survey and Candidate Gene Re-Sequencing Identifies Novel Exstrophy Candidate Genes and Implicates LZTR1 in Disease Formation. Biomolecules. 2023 Jul 13;13(7):1117.

Krüger J, Fischer A, Breunig M, Allgöwer C, Schulte L, Merkle J, Mulaw MA, Okeke N, Melzer MK, Morgenstern C, Azoitei N, Seufferlein T, Barth TF, Siebert R, Hohwieler M, Kleger A. DNA methylation-associated allelic inactivation regulates Keratin 19 gene expression during pancreatic development and carcinogenesis. J Pathol. 2023 Oct;261(2):139-155.

Kuckuck EC, Hennenlotter J, Todenhöfer T, Brünn LA, Rass GC, Stenzl A, Hakenberg OW, Roghmann F, Goebell PJ, Grimm MO, Pycha A, Bolenz C, Burger M, Benderska-Söder N, Schmitz-Dräger BJ. Discriminative capacity of guideline recommendations in the assessment of patients with asymptomatic microhematuria. Urol Oncol. 2023 May;41(5):254.e1-254.e8.

Leinert C, Fotteler M, Kocar TD, Dallmeier D, Kestler HA, Wolf D, Gebhard F, Uihlein A, Steger F, Kilian R, Mueller-Stierlin AS, Michalski CW, Mihaljevic A, Bolenz C, Zengerling F, Leinert E, Schütze S, Hoffmann TK, Onder G, Andersen-Ranberg K, O'Neill D, Wehling M, Schobel J, Swoboda W, Denkinger M; SURGE-Ahead Study Group. Supporting SURgery with GEriatric Co-Management and AI (SURGE-Ahead): A study protocol for the development of a digital geriatrician. PLoS One. 2023 Jun 16;18(6):e0287230.

Lisson CS, Manoj S, Wolf D, Lisson CG, Schmidt SA, Beer M, Thaiss W, Bolenz C, Zengerling F, Goetz M. Radiomics and Clinicopathological Characteristics for Predicting Lymph Node Metastasis in Testicular Cancer. Cancers (Basel). 2023 Nov 29;15(23):5630.

Maisch P, Koll F, Bolenz C, Chun FK, Gschwend JE, Schmid SC. Combination of radiation and immunotherapy in the treatment of genitourinary malignancies: A systematic review and meta-analysis. Urol Oncol. 2023 May;41(5):219-232.

Maisch P, Hwang EC, Kim K, Narayan VM, Bakker C, Kunath F, Dahm P. Immunotherapy for advanced or metastatic urothelial carcinoma. Cochrane Database Syst Rev. 2023 Oct9;10(10):CD013774.

Melzer MK, Kleger A. Pancreatic acinar heterogeneity hijacks carcinogenesis and homeostasis. Cell Stem Cell. 2023 Aug 3;30(8):1003-1005.

Melzer MK, Schirge S, Gout J, Arnold F, Srinivasan D, Burtscher I, Allgöwer C, Mulaw M, Zengerling F, Günes C, Lickert H, Christoffels VM, Liebau S, Wagner M, Seufferlein T, Bolenz C, Moon AM, Perkhofer L, Kleger A. TBX3 is dynamically expressed in pancreatic organogenesis and fine-tunes regeneration. BMC Biol. 2023 Mar 20;21(1):55.

Melzer MK, Resheq Y, Navaee F, Kleger A. The application of pancreatic cancer organoids for novel drug discovery. Expert Opin Drug Discov. 2023 Apr;18(4):429-444.

Merz S, Breunig M, Melzer MK, Heller S, Wiedenmann S, Seufferlein T, Meier M, Krüger J, Mulaw MA, Hohwieler M, Kleger A. Single-cell profiling of GP2-enriched pancreatic progenitors to simultaneously create acinar, ductal, and endocrine organoids. Theranostics. 2023 Mar 21;13(6):1949-1973.

Miernik A, Bolenz C. [Use of modern imaging in treatment planning for urological interventions]. Urologie. 2023 Nov;62(11):1131-1132.

Muranyi, Andrew; Ammer, Tobias; Kechter, Anna; Rawat, Vijay PS; Sinha, Amit; Gonzalez-Menendez, Irene; Quintanilla-Martinez, Leticia; Azoitei, Anca; Günes, Cagatay; Mupo, Annalisa; ,Npm1 haploinsufficiency in collaboration with MEIS1 is sufficient to induce AML in mice,Blood Advances,7,3,351-364,2023.

Nestler T, Hircin E, Siech C, Moharam N, Mattigk A, Borgmann H, Kuru TH, Salem J. Evaluierung des GeSRU-Steps-Lehrvideokonzepts (German Society of Residents in Urology e. V.) [Evaluation of the GeSRU-Steps educational video concept (German Society of Residents in Urology e. V.)]. Urologie. 2023 Dec 28. German.

Pal SK, Albiges L, Tomczak P, Suárez C, Voss MH, de Velasco G, Chahoud J, Mochalova A, Procopio G, Mahammedi H, Zengerling F, Kim C, Osawa T, Angel M, Gupta S, Khan O, Bergthold G, Liu B, Kalaitzidou M, Huseni M, Scheffold C, Powles T, Choueiri TK. Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2023 Jul 15;402(10397):185-195.

Schneidewind L, Kiss B, Zengerling F, Borkowetz A, Graf S, Kranz J, Dräger DL, Graser A, Bellut L, Uhlig A. Gender-specific outcomes in immune checkpoint inhibitor therapy for advanced or metastatic urothelial cancer: a systematic review and meta-analysis. J Cancer Res Clin Oncol. 2023 Sep;149(11):9399-9408.

Schreen W, Zengerling F. Einsatz von Cranberries zur Vorbeugung von Harnwegsinfektionen : Ein Kommentar zur Cochrane Studie [Use of cranberries to prevent urinary tract infections : Commentary on the Cochrane review]. Urologie. 2023 Dec;62(12):1322-1325. German.

Schreen W, Huch B, Vogele D, Zengerling F. Ein Fahrradsturz mit Folgen [A bicycle fall with consequences]. Urologie. 2023 Dec;62(12):1309-1314. German.

Söhngen C, Thomas DJ, Skowron MA, Bremmer F, Eckstein M, Stefanski A, Driessen MD, Wakileh GA, Stühler K, Altevogt P, Theodorescu D, Klapdor R, Schambach A, Nettersheim D. CD24 targeting with NK-CAR immunotherapy in testis, prostate, renal and (luminal-type) bladder cancer and identification of direct CD24 interaction partners. FEBS J. 2023 Oct;290(20):4864-4876.

Strauß AS, Bolenz C, Beer AJ, Zengerling F, Beer M, Miksch J. Urologie. [Opportunities for prostate-specific membrane antigen hybrid imaging in prostate cancer]. 2023 Nov;62(11):1153-1159.

Struck JP, Hennig MJP, Hupe MC, Moharam N, Paffenholz P, Nestler T, Frank T, Worst TS, Grabbert M, Pohlmann PF, Dogan S, Hofbauer SL, Kalogirou C, Mattigk A, Brandt MP, Krabbe LM, Reis H, Dressler FF, Kramer MW, Salem J. Discrepancy between German S3 Guideline Recommendations and Daily Urologic Practice in the Management of Nonmuscle Invasive Bladder Cancer: Results of a Binational Survey. Urol Int. 2023;107(1):35-45.

Thaiss W, Zengerling F, Friedrich J, Hechler V, Grunert M, Bolenz C, Wiegel T, Beer AJ, Prasad V. Personalized [177Lu]Lutetium-PSMA Therapy for Patients with Pre-Treated Castration-Resistant Prostate Cancer: A Single Institution Experience from a Comprehensive Cancer Centre. Cancers (Basel). 2023 Jun 16;15(12):3216.

Wakileh GA, Bierholz P, Kotthoff M, Skowron MA, Bremmer F, Stephan A, Anbuhl SM, Heukers R, Smit MJ, Ströbel P, Nettersheim D. , Molecular characterization of the CXCR4 / CXCR7 axis in germ cell tumors and its targetability using nanobody-drug-conjugates. Exp Hematol Oncol. 2023 Nov 23;12(1):96.

Wang X, Liu J, Azoitei A, Eiseler T, Meessen S, Jiang W, Zheng X, Makori AW, Eckstein M, Hartmann A, Stilgenbauer S, Elati M, Hohwieler M, Kleger A, John A, Zengerling F, Wezel F, Bolenz C, Günes C. Loss of ORP3 induces aneuploidy and promotes bladder cancer cell invasion through deregulated microtubule and actin dynamics. Cell Mol Life Sci. 2023 Sep 22;80(10):299.

Zschäbitz S, Biernath N, Hilser T, Höllein A, Zengerling F, Cascucelli J, Paffenholz P, Seidl D, Lutz C, Schlack K, Kingreen D, Klümper N, Ivanyi P, von Amsberg G, Heers H, Roghmann F, Tauber RL, Cathomas R, Hofer L, Niegisch G, Klee M, Ehrenberg R, Hassler A, Hadaschik BA, Grünwald V, Darr C. Enfortumab Vedotin in Metastatic Urothelial Carcinoma: Survival and Safety in a European Multicenter Real-world Patient Cohort. Eur Urol Open Sci. 2023 May 17;53:31-37.

2022

Behling, M., F. Wezel, and P. P. Pott. "Miniature Low-Cost Gamma-Radiation Sensor for Localization of Radioactively Marked Lymph Nodes." Proc Inst Mech Eng H 236, no. 3 (Mar 2022): 406-15.

Bekele, B. M., V. Schowel-Wolf, J. Kieshauer, A. Marg, A. Busjahn, S. Davis, G. Nugent, A. K. Ebert, and S. Spuler. "Human Primary Muscle Stem Cells Regenerate Injured Urethral Sphincter in Athymic Rats." Animal Model Exp Med 5, no. 5 (Oct 2022): 453-60.

Bolenz, C., H. Kubler, and C. Ohlmann. "[Multimodal Treatment Strategies for Urologic Cancers]." Urologie 61, no. 12 (Dec 2022): 1313-14.

Bolenz, C., C. H. Ohlmann, and J. Gschwend. "[Do's and Dont's for Radical Cystectomy and Urinary Diversion - How to Minimise Postoperative Complications]." Aktuelle Urol 53, no. 2 (Apr 2022): 159-66.

Brandt, M. P., C. Ruf, K. P. Dieckmann, I. Syring, C. Ruckes, T. Nestler, H. U. Schmelz, R. Dotzauer, A. Hiester, P. Albers, D. Nettersheim, C. Bolenz, S. H. Loosen, A. Heidenreich, D. Pfister, A. Haferkamp, F. Zengerling, P. Paffenholz, and Penile Cancer Group Gesru Academics Testis. "Clinical Characteristics, Treatment Patterns and Relapse in Patients with Clinical Stage Is Testicular Cancer." World J Urol 40, no. 2 (Feb 2022): 327-34.

Breidenbach, C., L. Ansmann, N. T. Sibert, S. Wesselmann, S. Dieng, E. G. Carl, G. Feick, C. Stoklossa, A. Taubert, A. Pomery, B. Beyer, A. Blana, M. Brock, F. Distler, M. Enge, A. A. Gaber, C. Gilfrich, A. Hinkel, B. Kaftan, T. Knoll, F. Kunath, S. J. Oostdam, I. Peters, B. Polat, V. Schrodi, F. Zengerling, and C. Kowalski. "Predictors for the Utilization of Social Service Counseling by Prostate Cancer Patients." Support Care Cancer 30, no. 3 (Mar 2022): 2327-39.

Busch, J., S. Schmidt, P. Albers, J. Heinzelbecker, S. Kliesch, J. Lackner, D. Pfister, C. Ruf, C. Winter, F. Zengerling, and D. Beyersdorff. "Can Magnetic Resonance Imaging Replace Conventional Computerized Tomography for Follow-up of Patients with Testicular Cancer? A Systematic Review." World J Urol 40, no. 12 (Dec 2022): 2843-52.

Dieckmann, K. P., C. Dumlupinar, A. Radtke, C. Matthies, R. Pichler, P. Paffenholz, J. Sommer, A. Winter, F. Zengerling, F. Hennig, C. Wulfing, and G. Belge. "Associations of Serum Levels of Microrna-371a-3p (M371) with Risk Factors for Progression in Nonseminomatous Testicular Germ Cell Tumours Clinical Stage 1." World J Urol 40, no. 2 (Feb 2022): 317-26.

Dieckmann, K. P., T. Pokrivcak, L. Geczi, D. Niehaus, I. Dralle-Filiz, C. Matthies, T. Dienes, S. Zschabitz, P. Paffenholz, T. Gschliesser, R. Pichler, M. Mego, P. Bader, F. Zengerling, J. Heinzelbecker, P. Krausewitz, S. Krege, G. Aurilio, C. Aksoy, M. Hentrich, C. Seidel, P. Torzsok, T. Nestler, M. Majewski, A. Hiester, T. Buchler, S. Vallet, H. Studentova, S. Schonburg, D. Niedersuss-Beke, J. Ring, E. Trenti, A. Heidenreich, C. Wulfing, H. Isbarn, U. Pichlmeier, and M. Pichler. "Single-Course Bleomycin, Etoposide, and Cisplatin (1xbep) as Adjuvant Treatment in Testicular Nonseminoma Clinical Stage 1: Outcome, Safety, and Risk Factors for Relapse in a Population-Based Study." Ther Adv Med Oncol 14 (2022): 17588359221086813.

Dieckmann, K. P., C. G. Ruf, R. Gubitz, C. Wulfing, and F. Zengerling. "[Follow-up of Testicular Germ Cell Tumors-Historical Aspects and Current Recommendations]." Urologe A 61, no. 5 (May 2022): 484-94.

Erlmeier, F., N. Klumper, L. Landgraf, P. L. Strissel, R. Strick, D. Sikic, H. Taubert, S. Wach, C. I. Geppert, V. Bahlinger, J. Breyer, M. Ritter, C. Bolenz, F. Roghmann, P. Erben, K. Schwamborn, R. M. Wirtz, T. Horn, B. Wullich, M. Holzel, A. Hartmann, J. E. Gschwend, W. Weichert, and M. Eckstein. "Spatial Immunephenotypes of Distant Metastases but Not Matched Primary Urothelial Carcinomas Predict Response to Immune Checkpoint Inhibition." Eur Urol 83, no. 2 (Feb 2023): 133-42.

Gonzalez Padilla, D. A., J. D. Subiela, D. M. Carrion, F. Esperto, J. Gomez Rivas, S. Khadhouri, G. Mantica, A. Mattigk, B. Pradere, M. Rodriguez Socarras, E. Segui Moya, J. Y. Teoh, L. Tortolero-Blanco, T. Ucar, and P. Dahm. "Evidence-Based Medicine: Perceptions, Attitudes, and Skills among European Urology Residents." Eur Urol Open Sci 45 (Nov 2022): 44-49.

Grimm, M. O., B. J. Schmitz-Drager, U. Zimmermann, C. B. Grun, G. B. Baretton, M. Schmitz, S. Foller, K. Leucht, M. Schostak, F. Zengerling, U. Schumacher, W. Loidl, and J. Meran. "Tailored Immunotherapy Approach with Nivolumab in Advanced Transitional Cell Carcinoma." J Clin Oncol 40, no. 19 (Jul 1 2022): 2128-37.

Harke, N. N., C. Wagner, R. M. Hermann, B. A. Hadaschik, J. P. Radtke, A. Altay-Langguth, S. Aufderklamm, C. Bach, M. Becker-Schiebe, A. Blana, F. Bruns, S. Buse, S. E. Combs, C. L. Engels, E. Ezzibdeh, M. Fiedler, L. A. Fischer, M. Farzat, A. Frismann, M. M. Heck, C. Henkenberens, M. C. Roesch, C. Kading, G. Klautke, P. Krausewitz, M. A. Kuczyk, C. Leitsmann, S. Lettmaier, S. Mahjoub, A. Manseck, D. Medenwald, A. Meyer, O. Micke, R. Moritz, M. Ott, I. Peters, S. Pokupic, D. Porres, F. Preisser, K. Reichel, A. Schneider, C. Schwentner, S. Scobioala, M. Truss, D. Wegener, F. Wezel, K. Willborn, J. H. Witt, A. Wittig, M. Wittlinger, H. A. Wolff, V. Zimmermanns, and H. Christiansen. "Lessons Learned after One Year of Covid-19 from a Urologist and Radiotherapist View: A German Survey on Prostate Cancer Diagnosis and Treatment." PLoS One 17, no. 6 (2022): e0269827.

Heinzelbecker, J., S. Schmidt, J. Lackner, J. Busch, C. Bokemeyer, J. Classen, A. Dieing, O. Hakenberg, S. Krege, A. Papachristofilou, D. Pfister, C. Ruf, H. Schmelz, H. Schmidberger, R. Souchon, C. Winter, F. Zengerling, S. Kliesch, P. Albers, and C. Oing. "Therapy of Clinical Stage Iia and Iib Seminoma: A Systematic Review." World J Urol 40, no. 12 (Dec 2022): 2829-41.

Hoeh, B., P. Schmucker, N. Klumper, O. Hahn, P. Zeuschner, S. Banek, P. I. Karakiewicz, J. Ellinger, J. Heinzelbecker, M. Holzel, A. Strauss, F. Zengerling, A. Mattigk, and C. Kalogirou. "Comparison of First-Line Anti-Pd-1-Based Combination Therapies in Metastatic Renal-Cell Carcinoma: Real-World Experiences from a Retrospective, Multi-Institutional Cohort." Urol Int 106, no. 11 (2022): 1150-57

Klein, J. T., A. John, L. Bohnert, M. D. Enderle, W. Linzenbold, and C. Bolenz. "Improving the Quality of Human Upper Urinary Tract Specimens by Cryobiopsy." Front Oncol 12 (2022): 810367.

Kloth, C., F. Wezel, T. Breining, and A. Beck. "[Title_English]." MMW Fortschr Med 164, no. 16 (Sep 2022): 11.

Klumper, N., D. J. Ralser, J. Ellinger, F. Roghmann, J. Albrecht, E. Below, A. Alajati, D. Sikic, J. Breyer, C. Bolenz, F. Zengerling, P. Erben, K. Schwamborn, R. M. Wirtz, T. Horn, D. Nagy, M. Toma, G. Kristiansen, T. Buttner, O. Hahn, V. Grunwald, C. Darr, E. Erne, S. Rausch, J. Bedke, K. Schlack, M. Abbas, S. Zschabitz, C. Schwab, A. Mustea, P. Adam, A. Manseck, B. Wullich, M. Ritter, A. Hartmann, J. Gschwend, W. Weichert, F. Erlmeier, M. Holzel, and M. Eckstein. "Membranous Nectin-4 Expression Frequently Decreases During Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance." Clin Cancer Res (Dec 19 2022).

Klumper, N., D. Sikic, J. Saal, T. Buttner, F. Goldschmidt, J. Jarczyk, P. Becker, P. Zeuschner, M. Weinke, C. Kalogirou, J. Breyer, M. Burger, P. Nuhn, K. Tully, F. Roghmann, C. Bolenz, F. Zengerling, R. M. Wirtz, M. Muders, G. Kristiansen, T. Bald, J. Ellinger, B. Wullich, M. Holzel, A. Hartmann, P. Erben, M. Ritter, and M. Eckstein. "C-Reactive Protein Flare Predicts Response to Anti-Pd-(L)1 Immune Checkpoint Blockade in Metastatic Urothelial Carcinoma." Eur J Cancer 167 (May 2022): 13-22.

Kuckuck, E. C., J. Hennenlotter, T. Todenhofer, L. A. Brunn, G. C. Rass, A. Stenzl, O. W. Hakenberg, F. Roghmann, P. J. Goebell, M. O. Grimm, A. Pycha, C. Bolenz, M. Burger, N. Benderska-Soder, and B. J. Schmitz-Drager. "Discriminative Capacity of Guideline Recommendations in the Assessment of Patients with Asymptomatic Microhematuria." Urol Oncol (Oct 20 2022).

Maisch, P., F. Koll, C. Bolenz, F. K. Chun, J. E. Gschwend, and S. C. Schmid. "Combination of Radiation and Immunotherapy in the Treatment of Genitourinary Malignancies: A Systematic Review and Meta-Analysis." Urol Oncol (Nov 10 2022).

Mattigk, A., L. Bellut, U. V. Albrecht, U. von Jan, and J. P. Struck. "[Great Potential, Little Substance : Overview of Quality and Quantity of Urological Apps in the German App Store]." Urologe A 61, no. 2 (Feb 2022): 125-32.

Mattigk, A., L. Bellut, U. V. Albrecht, U. von Jan, and J. P. Struck. "[Not Available]." Urologie 61, no. 6 (Jun 2022): 663.

Mattigk, A. and A. Miernik. "[Digitalization-Benefits for Urology]." Urologe A 61, no. 2 (Feb 2022): 115-16.

Mayr, R., M. Eckstein, R. M. Wirtz, A. Santiago-Walker, M. Baig, R. Sundaram, J. C. Carcione, R. Stoehr, A. Hartmann, C. Bolenz, M. Burger, W. Otto, P. Erben, and J. Breyer. "Prognostic and Predictive Value of Fibroblast Growth Factor Receptor Alterations in High-Grade Non-Muscle-Invasive Bladder Cancer Treated with and without Bacillus Calmette-Guerin Immunotherapy." Eur Urol 81, no. 6 (Jun 2022): 606-14.

Meessen, S., G. Najjar, A. Azoitei, S. Iben, C. Bolenz, and C. Gunes. "A Comparative Assessment of Replication Stress Markers in the Context of Telomerase." Cancers (Basel) 14, no. 9 (Apr 28 2022).

Melzer, M. K., M. Breunig, F. Arnold, F. Wezel, A. Azoitei, E. Roger, J. Kruger, J. Merkle, L. Schutte, Y. Resheq, M. Hanle, V. Zehe, F. Zengerling, N. Azoitei, L. Klein, F. Penz, S. K. Singh, T. Seufferlein, M. Hohwieler, C. Bolenz, C. Gunes, J. Gout, and A. Kleger. "Organoids at the Pub: The Porcine Urinary Bladder Serves as a Pancreatic Niche for Advanced Cancer Modeling." Adv Healthc Mater 11, no. 11 (Jun 2022): e2102345.

Melzer, M. K., M. Breunig, P. Lopatta, M. Hohwieler, S. Merz, A. Azoitei, C. Gunes, C. Bolenz, and A. Kleger. "Protocol to Use De-Epithelialized Porcine Urinary Bladder as a Tissue Scaffold for Propagation of Pancreatic Cells." STAR Protoc 3, no. 4 (Dec 16 2022): 101869.

Melzer, M. K. and A. Kleger. "Acute Pancreatitis: Murine Model Systems Unravel Disease-Modifying Genes with Potential Implications for Diagnostics and Patient Stratification." United European Gastroenterol J 10, no. 7 (Sep 2022): 618-19.

Melzer, M. K., E. Roger, and A. Kleger. "State-Matched Organoid Models to Fight Pancreatic Cancer." Trends Cancer 8, no. 6 (Jun 2022): 445-47.

Melzer, M. K., V. Zehe, F. Zengerling, F. Wezel, C. Gunes, P. Maisch, and C. Bolenz. "[Organoids as a Milestone on the Way to Personalized Treatment of Urothelial Carcinoma: A Systematic Review]." Urologie 61, no. 7 (Jul 2022): 745-52.

Mingardo, E., G. Beaman, P. Grote, A. Nordenskjold, W. Newman, A. S. Woolf, M. Eckstein, A. C. Hilger, G. C. Dworschak, W. Rosch, A. K. Ebert, R. Stein, A. Brusco, M. Di Grazia, A. Tamer, F. M. Torres, J. L. Hernandez, P. Erben, C. Maj, J. M. Olmos, J. A. Riancho, C. Valero, I. C. Hostettler, H. Houlden, D. J. Werring, J. Schumacher, J. Gehlen, A. S. Giel, B. C. Buerfent, S. Arkani, E. Akesson, E. Rotstein, M. Ludwig, G. Holmdahl, E. Giorgio, A. Berettini, D. Keene, R. M. Cervellione, N. Younsi, M. Ortlieb, J. Oswald, B. Haid, M. Promm, C. Neissner, K. Hirsch, M. Stehr, F. M. Schafer, E. Schmiedeke, T. M. Boemers, Ialm van Rooij, W. F. J. Feitz, C. L. M. Marcelis, M. Lacher, J. Nelson, B. Ure, C. Fortmann, D. P. Gale, M. M. Y. Chan, K. U. Ludwig, M. M. Nothen, S. Heilmann, N. Zwink, E. Jenetzky, B. Odermatt, M. Knapp, and H. Reutter. "A Genome-Wide Association Study with Tissue Transcriptomics Identifies Genetic Drivers for Classic Bladder Exstrophy." Commun Biol 5, no. 1 (Nov 9 2022): 1203.

Muller, M. R., A. Burmeister, M. A. Skowron, A. Stephan, F. Bremmer, G. A. Wakileh, P. Petzsch, K. Kohrer, P. Albers, and D. Nettersheim. "Therapeutical Interference with the Epigenetic Landscape of Germ Cell Tumors: A Comparative Drug Study and New Mechanistical Insights." Clin Epigenetics 14, no. 1 (Jan 7 2022): 5.

Papachristofilou, A., J. Bedke, S. Hayoz, U. Schratzenstaller, M. Pless, M. Hentrich, S. Krege, A. Lorch, D. M. Aebersold, P. M. Putora, D. R. Berthold, D. Zihler, F. Zengerling, A. Dieing, A. C. Mueller, C. Schaer, C. Biaggi, S. Gillessen, and R. Cathomas. "Single-Dose Carboplatin Followed by Involved-Node Radiotherapy for Stage Iia and Stage Iib Seminoma (Sakk 01/10): A Single-Arm, Multicentre, Phase 2 Trial." Lancet Oncol 23, no. 11 (Nov 2022): 1441-50.

Pereira-Lourenco, M., T. Ucar, S. Nikles, K. H. Pang, J. Almeida, D. M. Carrion, F. Esperto, M. J. Freire, D. Karsza, G. Mantica, A. Mattigk, M. Rodriguez Socarras, and J. G. Rivas. "Annual Educational Expenses of European Urology Residents and the Role of Sponsorship in Urology Training: A Survey-Based Analysis." Cent European J Urol 75, no. 4 (2022): 418-28.

Pfister, D., K. Oechsle, S. Schmidt, J. Busch, C. Bokemeyer, A. Heidenreich, J. Heinzelbecker, C. Ruf, C. Winter, F. Zengerling, S. Kliesch, P. Albers, and C. Oing. "First-Line Salvage Treatment Options for Germ Cell Tumor Patients Failing Stage-Adapted Primary Treatment : A Comprehensive Review Compiled by the German Testicular Cancer Study Group." World J Urol 40, no. 12 (Dec 2022): 2853-61.

Riedel, F., M. Munker, F. Roghmann, J. Breyer, M. J. Schnabel, M. Burger, D. Sikic, T. Buttner, M. Ritter, K. Hiller, F. Wezel, C. Bolenz, and F. Zengerling. "Efficacy of Vinflunine for Patients with Metastatic Urothelial Cancer after Immune Checkpoint Inhibitor Pretreatment-a Retrospective Multicenter Analysis." Cancers (Basel) 14, no. 12 (Jun 9 2022).

Ruf, C. G., S. Schmidt, S. Kliesch, C. Oing, D. Pfister, J. Busch, J. Heinzelbecker, C. Winter, F. Zengerling, P. Albers, K. Oechsle, S. Krege, J. Lackner, and K. P. Dieckmann. "Testicular Germ Cell Tumours' Clinical Stage I: Comparison of Surveillance with Adjuvant Treatment Strategies Regarding Recurrence Rates and Overall Survival-a Systematic Review." World J Urol 40, no. 12 (Dec 2022): 2889-900.

Seckin, M., I. Ricard, T. Raiser, N. Heitkamp, A. Ebert, C. Prix, J. Levin, J. Diehl-Schmid, L. Riedl, C. Rossmeier, N. Hoen, M. L. Schroeter, A. Marschhauser, H. Obrig, T. Benke, J. Kornhuber, K. Fliessbach, A. Schneider, J. Wiltfang, H. Jahn, K. Fassbender, J. Prudlo, M. Lauer, T. Duning, C. Wilke, M. Synofzik, S. Anderl-Straub, E. Semler, J. Lombardi, B. Landwehrmeyer, A. Ludolph, M. Otto, A. Danek, and Ftld consortium German. "Utility of the Repeat and Point Test for Subtyping Patients with Primary Progressive Aphasia." Alzheimer Dis Assoc Disord 36, no. 1 (Jan-Mar 01 2022): 44-51.

Seidel, C., M. Hentrich, S. Zschabitz, P. Paffenholz, A. Heidenreich, T. Nestler, B. Tran, S. Fischer, G. Daugaard, S. Ochsenreither, M. Brito, F. Zengerling, C. Schwab, C. Bokemeyer, and C. Oing. "Peritoneal Carcinosis in Male Germ Cell Tumor Patients: A Registry Study Compiled by the German Testicular Cancer Study Group (Gtcsg)." World J Urol 40, no. 2 (Feb 2022): 355-61.

Skowron, M. A., T. K. Becker, L. Kurz, S. Jostes, F. Bremmer, F. Fronhoffs, K. Funke, G. A. Wakileh, M. R. Muller, A. Burmeister, T. Lenz, A. Stefanski, K. Stuhler, P. Petzsch, K. Kohrer, P. Altevogt, P. Albers, G. Kristiansen, H. Schorle, and D. Nettersheim. "The Signal Transducer Cd24 Suppresses the Germ Cell Program and Promotes an Ectodermal Rather Than Mesodermal Cell Fate in Embryonal Carcinomas." Mol Oncol 16, no. 4 (Feb 2022): 982-1008.

Skowron, M. A., K. Eul, A. Stephan, G. F. Ludwig, G. A. Wakileh, A. Bister, C. Sohngen, K. Raba, P. Petzsch, G. Poschmann, E. O. Kuffour, D. Degrandi, S. Ali, C. Wiek, H. Hanenberg, C. Munk, K. Stuhler, K. Kohrer, E. Mass, and D. Nettersheim. "Profiling the 3d Interaction between Germ Cell Tumors and Microenvironmental Cells at the Transcriptome and Secretome Level." Mol Oncol 16, no. 17 (Sep 2022): 3107-27.

Vazeou, A., S. R. Tittel, O. Kordonouri, N. H. Birkebaek, V. Iotova, B. Piccini, S. Seget, P. K. Guness, D. M. Maahs, and G. S. Stergiou. "Increased Prevalence of Cardiovascular Risk Factors in Children and Adolescents with Type 1 Diabetes and Hypertension: The Sweet International Database." Diabetes Obes Metab 24, no. 12 (Dec 2022): 2420-30.

Wakileh, G. A., C. Ruf, A. Heidenreich, K. P. Dieckmann, C. Lisson, V. Prasad, C. Bolenz, and F. Zengerling. "Contemporary Options and Future Perspectives: Three Examples Highlighting the Challenges in Testicular Cancer Imaging." World J Urol 40, no. 2 (Feb 2022): 307-15.

Wang, W., X. Zheng, A. Azoitei, A. John, F. Zengerling, F. Wezel, C. Bolenz, and C. Gunes. "The Role of Tks5 in Chromosome Stability and Bladder Cancer Progression." Int J Mol Sci 23, no. 22 (Nov 18 2022).

Winter, C., F. Zengerling, J. Busch, J. Heinzelbecker, D. Pfister, C. Ruf, J. Lackner, P. Albers, S. Kliesch, S. Schmidt, and C. Bokemeyer. "How to Classify, Diagnose, Treat and Follow-up Extragonadal Germ Cell Tumors? A Systematic Review of Available Evidence." World J Urol 40, no. 12 (Dec 2022): 2863-78.

Wolff, I., M. Burchardt, C. Gilfrich, J. Peter, M. Baunacke, C. Thomas, J. Huber, R. Gillitzer, D. Sikic, C. Fiebig, J. Steinestel, P. Schifano, N. Lobig, C. Bolenz, F. A. Distler, C. Huettenbrink, M. Janssen, D. Schilling, B. Barakat, N. N. Harke, C. Fuhrmann, A. Manseck, R. Wagenhoffer, E. Geist, L. Blair, J. Pfitzenmaier, B. Reinhardt, B. Hoschke, M. Burger, J. Brundl, M. J. Schnabel, M. May, and Improve Study Group. "Patients Regret Their Choice of Therapy Significantly Less Frequently after Robot-Assisted Radical Prostatectomy as Opposed to Open Radical Prostatectomy: Patient-Reported Results of the Multicenter Cross-Sectional Improve Study." Cancers (Basel) 14, no. 21 (Oct 30 2022).

Zengerling, F. "[Surgical or Radiological Treatment of Varicoceles in Subfertile Men]." Urologie 61, no. 12 (Dec 2022): 1382-86.

Zengerling, F., D. Beyersdorff, J. Busch, J. Heinzelbecker, D. Pfister, C. Ruf, C. Winter, P. Albers, S. Kliesch, and S. Schmidt. "Prognostic Factors in Patients with Clinical Stage I Nonseminoma-Beyond Lymphovascular Invasion: A Systematic Review." World J Urol 40, no. 12 (Dec 2022): 2879-87.

2021

Zheng X, Wezel F, Azoitei A, Meessen S, Wang W, Najjar G, Wang X, Kraus J, Kestler H, John A, Zengerling F, Bolenz C and Günes C. Shorter Leukocyte Telomere Length Is Associated with Worse Survival of Patients with Bladder Cancer and Renal Cell Carcinoma.Cancers. (Basel). 2021 July. Accepted

Walter K, Rodriguez-Aznar E, Ferreira MSV, Frappart PO, Dittrich T, Tiwary K, Meessen S, Lerma L, Daiss N, Schulte LA, Najafova Z, Arnold F, Usachov V, Azoitei N, Erkan M, Lechel A, Brümmendorf TH, Seufferlein T, Kleger A, Tabarés E, Günes C, Johnsen SA, Beier F, Sainz B Jr, Hermann PC. Telomerase and Pluripotency Factors Jointly Regulate Stemness in Pancreatic Cancer Stem Cells. Cancers (Basel). 2021 Jun 23;13(13):3145. doi: 10.3390/cancers13133145

Schneider L, Junnan L, Zhang C, Azoitei A, Meessen S, Zheng X, Cremer C, Gorzelanny C, Kempe-Gonzales S, Brunner C, Wezel F, Bolenz C, Gunes C*, John A. The Role of Interleukin-1-Receptor-Antagonist in Bladder Cancer Cell Migration and Invasion. Int J Mol Sci. 2021. Manuscript ID: ijms-1231167

Breunig M, Merkle J, Wagner M, Melzer MK, Barth TFE, Engleitner T, Krumm J, Wiedenmann S, Cohrs CM, Perkhofer L, Jain G, Krüger J, Hermann PC, Schmid M, Madácsy T, Varga Á, Griger J, Azoitei N, Müller M, Wessely O, Robey PG, Heller S, Dantes Z, Reichert M, Günes C, Bolenz C, Kuhn F, Maléth J, Speier S, Liebau S, Sipos B, Kuster B, Seufferlein T, Rad R, Meier M, Hohwieler M, Kleger A. Modeling plasticity and dysplasia of pancreatic ductal organoids derived from human pluripotent stem cells. Cell Stem Cell. 2021 Apr 15:S1934-5909(21)00111-9. doi: 10.1016/j.stem.2021.03.005. Epub ahead of print. PMID: 33915078.

Wezel F, Lustig J, Azoitei A, Liu J, Meessen S, Najjar G, Zehe V, Faustmann P, Zengerling F, John A, Martini T, Bolenz C, Günes C. Grainyhead-Like 3 Influences Migration and Invasion of Urothelial Carcinoma Cells. Int J Mol Sci. 2021 Mar 15;22(6):2959. doi: 10.3390/ijms22062959. PMID: 33803949; PMCID: PMC8000182.

Deniz M, Zengerling F, Gundelach T, Moreno-Villanueva M, Bürkle A, Janni W, Bolenz C, Kostezka S, Marienfeld R, Benckendorff J, Friedl TWP, Wiesmüller L, Rall-Scharpf M. Age-related activity of Poly (ADP-Ribose) Polymerase (PARP) in men with localized prostate cancer. Mech Ageing Dev. 2021 Apr 19;196:111494. doi: 10.1016/j.mad.2021.111494. Epub ahead of print. PMID: 33887280.

Bolenz C, Vogel T, Morakis P, Mayr R, Marx M, Burger M. Uroonkologische Therapie in der ersten Welle der COVID-19-Pandemie : Was sagen uns die Krebsregister der deutschen Bundesländer? [Urologic cancer care during the first wave of the COVID-19 pandemic : Role of federal cancer registration in Germany]. Urologe A. 2021 Mar;60(3):291-300. German. doi: 10.1007/s00120-021-01454-3. Epub 2021 Feb 9. PMID: 33559692; PMCID: PMC7871312.

Kriegmair MC, Hein S, Schoeb DS, Zappe H, Suárez-Ibarrola R, Waldbillig F, Gruene B, Pohlmann PF, Praus F, Wilhelm K, Gratzke C, Miernik A, Bolenz C. Erweiterte Bildgebung in der urologischen Endoskopie [Enhanced imaging in urological endoscopy]. Urologe A. 2021 Jan;60(1):8-18. German. doi: 10.1007/s00120-020-01400-9. Epub 2020 Dec 10. Erratum in: Urologe A. 2021 Apr 20;: PMID: 33301070.

Diesinger T, Lautwein A, Bergler S, Buckert D, Renz C, Dvorsky R, Buko V, Kirko S, Schneider E, Kuchenbauer F, Kumar M, Günes C, Genze F, Büchele B, Simmet T, Haslbeck M, Masur K, Barth T, Müller-Enoch D, Wirth T, Haehner T. A New CYP2E1 Inhibitor, 12-Imidazolyl-1-dodecanol, Represents a Potential Treatment for Hepatocellular Carcinoma. Can J Gastroenterol Hepatol. 2021 Feb 2;2021:8854432. doi: 10.1155/2021/8854432. PMID: 33604316; PMCID: PMC7872744.

2020

Xu P, Richter J, Blatz A, Gärtner F, Alberts R, Azoitei A, Makori WA, Meessen S, Knippschild U, Günes C. Downregulation of ORP3 Correlates with Reduced Survival of Colon Cancer Patients with Advanced Nodal Metastasis and of Female Patients with Grade 3 Colon Cancer. Int J Mol Sci. 2020 Aug 16;21(16):5894.

Lang A, Whongsiri P, Yilmaz M, Lautwein T, Petzsch P, Greife A, Günes C, Köhrer K, Niegisch G, Hoffmann M, Schulz WA. Knockdown of UTX/KDM6A Enriches Precursor Cell Populations in Urothelial Cell Cultures and Cell Lines. Cancers (Basel). 2020 Apr 21;12(4). doi: 10.3390/cancers12041023.

John A, Günes C, Bolenz C, Vidal-Y-Sy S, Bauer AT, Schneider SW, Gorzelanny C. Bladder cancer-derived interleukin-1 converts the vascular endothelium into a pro-inflammatory and pro-coagulatory surface. BMC Cancer. 2020 Dec 2;20(1):1178. doi: 10.1186/s12885-020-07548-z. PMID: 33267794 Free PMC article.

Rinaldetti S, Worst TS, Rempel E, Kriegmair MC, Hartmann A, Porubsky S, Bolenz C, Erben P. Subtype specific expression and survival prediction of pivotal lncRNAs in muscle invasive bladder cancer. Sci Rep. 2020 Nov 24;10(1):20472. doi: 10.1038/s41598-020-77252-2. PMID: 33235218 Free PMC article.

Kramer MW, Bolenz C. [Rapid Progress in the treatment of bladder cancer: recent achievements]. Aktuelle Urol. 2020 Aug;51(4):342-343. doi: 10.1055/a-1137-1404. Epub 2020 Jul 29. PMID: 32726841 German. No abstract available.

Eckstein M, Strissel P, Strick R, Weyerer V, Wirtz R, Pfannstiel C, Wullweber A, Lange F, Erben P, Stoehr R, Bertz S, Geppert CI, Fuhrich N, Taubert H, Wach S, Breyer J, Otto W, Burger M, Bolenz C, Keck B, Wullich B, Hartmann A, Sikic D; BRIDGE Consortium e.V., Mannheim, Germany. Cytotoxic T-cell-related gene expression signature predicts improved survival in muscle-invasive urothelial bladder cancer patients after radical cystectomy and adjuvant chemotherapy. J Immunother Cancer. 2020 May;8(1):e000162. doi: 10.1136/jitc-2019-000162. PMID: 32448798 Free PMC article.

Melzer MK, Arnold F, Stifter K, Zengerling F, Azoitei N, Seufferlein T, Bolenz C, Kleger A. An Immunological Glance on Pancreatic Ductal Adenocarcinoma. Int J Mol Sci. 2020 May 8;21(9):3345. doi: 10.3390/ijms21093345. PMID: 32397303 Free PMC article. Review.

Sikic D, Eckstein M, Wirtz RM, Jarczyk J, Worst TS, Porubsky S, Keck B, Kunath F, Weyerer V, Breyer J, Otto W, Rinaldetti S, Bolenz C, Hartmann A, Wullich B, Erben P. FOXA1 Gene Expression for Defining Molecular Subtypes of Muscle-Invasive Bladder Cancer after Radical Cystectomy. J Clin Med. 2020 Apr 2;9(4):994. doi: 10.3390/jcm9040994. PMID: 32252315 Free PMC article.

John A, Robador JR, Vidal-Y-Sy S, Houdek P, Wladykowski E, Günes C, Bolenz C, Schneider SW, Bauer AT, Gorzelanny C. Urothelial Carcinoma of the Bladder Induces Endothelial Cell Activation and Hypercoagulation. Mol Cancer Res. 2020 Jul;18(7):1099-1109. doi: 10.1158/1541-7786.MCR-19-1041. Epub 2020 Mar 31. PMID: 32234826

Miksch J, Bottke D, Krohn T, Thamm R, Bartkowiak D, Solbach C, Bolenz C, Beer M, Wiegel T, Beer AJ, Prasad V. Interobserver variability, detection rate, and lesion patterns of 68Ga-PSMA-11-PET/CT in early-stage biochemical recurrence of prostate cancer after radical prostatectomy. Eur J Nucl Med Mol Imaging. 2020 Sep;47(10):2339-2347. doi: 10.1007/s00259-020-04718-w. Epub 2020 Mar 10. PMID: 32157427 Free PMC article.

Yeh HC, Margulis V, Singla N, Hernandez E, Panwar V, Woldu SL, Karam JA, Wood CG, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Roscigno M, Bolenz C, Bensalah K, Li CC, Ke HL, Li WM, Lee HY, Rapoport LM, Lotan Y, Kapur P, Shariat SF, Hsieh JT, Wu WJ. PTRF independently predicts progression and survival in multiracial upper tract urothelial carcinoma following radical nephroureterectomy. Urol Oncol. 2020 May;38(5):496-505. doi: 10.1016/j.urolonc.2019.11.010. Epub 2019 Dec 18. PMID: 31862213

Njeru SN, Kraus J, Meena JK, Lechel A, Katz SF, Kumar M, Knippschild U, Azoitei A, Wezel F, Bolenz C, Leithäuser F, Gollowitzer A, Omrani O, Hoischen C, Koeberle A, Kestler HA, Günes C, Rudolph KL. Aneuploidy-inducing gene knockdowns overlap with cancer mutations and identify Orp3 as a B-cell lymphoma suppressor. Oncogene. 2020 Feb;39(7):1445-1465. doi: 10.1038/s41388-019-1073-2. Epub 2019 Oct 28. PMID: 31659255

Hautmann RE, Bolenz C, Volkmer B. Unexpected Early Oncologic Mortality after Open Radical Cystectomy for Bladder Cancer: Who Is to Be Blamed? Urol Int. 2020;104(1-2):10-15. doi: 10.1159/000503398. Epub 2019 Sep 27. PMID: 31563906

Rudolph J, Martini T, Wezel F. [The impact of radical cystectomy on health-related quality of life and potential for optimisation].Aktuelle Urol. 2020 Aug;51(4):363-370. doi: 10.1055/a-1171-1213. Epub 2020 Jun 24.PMID: 32583388 German.

Ebert AK. [Bilateral reflux: contra "intravesical techniques"]. Aktuelle Urol. 2020 Apr;51(2):174-177. doi: 10.1055/a-0983-8240. Epub 2019 Dec 17. PMID: 31847008

Rieke JM, Zhang R, Braun D, Yilmaz Ö, Japp AS, Lopes FM, Pleschka M, Hilger AC, Schneider S, Newman WG, Beaman GM, Nordenskjöld A, Ebert AK, Promm M, Rösch WH, Stein R, Hirsch K, Schäfer FM, Schmiedeke E, Boemers TM, Lacher M, Kluth D, Gosemann JH, Anderberg M, Barker G, Holmdahl G, Läckgren G, Keene D, Cervellione RM, Giorgio E, Di Grazia M, Feitz WFJ, Marcelis CLM, Van Rooij IALM, Bökenkamp A, Beckers GMA, Keegan CE, Sharma A, Dakal TC, Wittler L, Grote P, Zwink N, Jenetzky E, Brusco A, Thiele H, Ludwig M, Schweizer U, Woolf AS, Odermatt B, Reutter H. SLC20A1 Is Involved in Urinary Tract and Urorectal Development. Front Cell Dev Biol. 2020 Aug 7;8:567. doi: 10.3389/fcell.2020.00567. eCollection 2020. PMID: 32850778

Blasl-Kling F, Dold SK, Klein JT, Wakileh GA, Humke U, Ebert AK. Guideline-adherence in the treatment of symptomatic urolithiasis in children and adolescents in southwestern Germany. BMC Urol. 2020 Jun 26;20(1):76. doi: 10.1186/s12894-020-00643-0. PMID: 32590972

Ebert AK, Zwink N, Reutter HM, Jenetzky E, Stein R, Hölscher AC, Lacher M, Fortmann C, Obermayr F, Fisch M, Mortazawi K, Schmiedeke E, Promm M, Hirsch K, Schäfer FM, Rösch WH. Treatment Strategies and Outcome of the Exstrophy-Epispadias Complex in Germany: Data From the German CURE-Net. Front Pediatr. 2020 May 19;8:174. doi: 10.3389/fped.2020.00174. eCollection 2020. PMID: 32509709

Carrion DM, Rodriguez-Socarrás ME, Mantica G, Esperto F, Cebulla A, Duijvesz D, Patruno G, Vásquez JL, Veneziano D, Díez-Sebastian J, Gozen AS, Palou J, Gómez Rivas J. Current status of urology surgical training in Europe: an ESRU-ESU-ESUT collaborative study. World J Urol. 2020 Jan;38(1):239-246. doi: 10.1007/s00345-019-02763-1. Epub 2019 Apr 13. PMID: 30982099.

Beck A, Wundrack FM, Mattigk A, Arnold H, Himmler M, Necknig U. Die Taskforce Beruf, Familie und Freizeit – Konzepte statt Schlagworte [Taskforce work-life balance-concepts instead of slogans]. Urologe A. 2020 Apr;59(4):484-486. German. doi: 10.1007/s00120-020-01161-5. PMID: 32128631.

Roghmann F, Breyer J, Kriegmair M, Wezel F, Burger M, Noldus J, Bolenz C; Bladder Cancer Research Initiative for Drug Targets Germany (BRIDGE) Consortium e. V.. [Quality assessment of radical cystectomy-opportunities, risks, challenges]. Urologe A. 2021 Feb;60(2):151-161. doi: 10.1007/s00120-020-01439-8. Epub 2021 Jan 22.PMID: 33481063 Review. German.

Pang KH, Carrion DM, Rivas JG, Mantica G, Mattigk A, Pradere B, Esperto F; European Society of Residents in Urology. The Impact of COVID-19 on European Health Care and Urology Trainees. Eur Urol. 2020 Jul;78(1):6-8. doi: 10.1016/j.eururo.2020.04.042. Epub 2020 Apr 27. PMID: 32376133; PMCID: PMC7183959.

Kriegmair MC, Hein S, Schoeb DS, Zappe H, Suárez-Ibarrola R, Waldbillig F, Gruene B, Pohlmann PF, Praus F, Wilhelm K, Gratzke C, Miernik A, Bolenz C. [Enhanced imaging in urological endoscopy]. Urologe A. 2021 Jan;60(1):8-18. doi: 10.1007/s00120-020-01400-9. Epub 2020 Dec 10. PMID: 33301070 Review. German.

Prasad V, Zengerling F, Steinacker JP, Bolenz C, Beer M, Wiegel T, Eiber M, Fleshner N, Beer AJ. First experiences with Lu-177 PSMA therapy in combination with Pembrolizumab or after pretreatment with Olaparib in single patients. J Nucl Med. 2020 Nov 27:jnumed.120.249029. doi: 10.2967/jnumed.120.249029. Online ahead of print. PMID: 33246977

Kriegmair MC, Bolenz C. Re: "Multiparametric cystoscopy: opportunities to enhance bladder cancer detection". Transl Androl Urol. 2020 Oct;9(5):2318-2319. doi: 10.21037/tau-20-915. PMID: 33216828 Free PMC article. No abstract available.

Michel MS, Himmler M, Necknig U, Kriegmair M, Speck T, Fichtner J, Steffens J, Borgmann H, Bolenz C, Tuellmann M, Ruppin S, Petersilie F, Rebmann U, König J, Westphal J, Goebell P, Leyh H, Borchers H. [Certified residency curriculum for the specialization training in urology from the German Society of Urology according to the 2018 Training Regulations (version of 20. September 2019)]. Urologe A. 2020 Dec;59(Suppl 2):135-140. doi: 10.1007/s00120-020-01367-7. PMID: 33141266 Free PMC article. German. No abstract available.

Kowalski C, Roth R, Carl G, Feick G, Oesterle A, Hinkel A, Steiner T, Brock M, Kaftan B, Borowitz R, Zantl N, Heidenreich A, Neisius A, Darr C, Bolenz C, Beyer B, Pfitzenmaier J, Brehmer B, Fichtner J, Haben B, Wesselmann S, Dieng S. A multicenter paper-based and web-based system for collecting patient-reported outcome measures in patients undergoing local treatment for prostate cancer: first experiences. J Patient Rep Outcomes. 2020 Jul 13;4(1):56. doi: 10.1186/s41687-020-00224-7. PMID: 32661594 Free PMC article.

Kriegmair MC, Younsi N, Hiller K, Leitsmann C, Kowalewski KF, Siegel F, Rothamel M, Ritter M, Bolenz C, Kriegmair M, Trojan L, Michel MS. Single- vs multiple-layer wound closure for flank incisions: results of a prospective, randomised, double-blinded multicentre study. BJU Int. 2021 Jan;127(1):64-70. doi: 10.1111/bju.15148. Epub 2020 Aug 18. PMID: 32564459

Suarez-Ibarrola R, Zengerling F, Haccius M, Lebentrau S, Schmid HP, Bier M, Lenart S, Distler FA, Resch I, Oelschlager M, May M, Bolenz C, Gratzke C, Miernik A, Wakileh GA. Adherence to European Association of Urology and National Comprehensive Cancer Network Guidelines Criteria for Inguinal and Pelvic Lymph Node Dissection in Penile Cancer Patients-A Survey Assessment in German-speaking Countries on Behalf of the European Prospective Penile Cancer Study Group. Eur Urol Focus. 2020 Feb 20:S2405-4569(20)30061-4. doi: 10.1016/j.euf.2020.02.005. Online ahead of print. PMID: 32089496

Mattigk A, Klein JT, Martini T. Testicular torsion in geriatric 82-year old man. Urol Case Rep. 2020 May 19;33:101258. doi: 10.1016/j.eucr.2020.101258. PMID: 32514401; PMCID: PMC7267712.

Carrion DM, Rodríguez-Socarrás ME, Mantica G, Pang KH, Esperto F, Mattigk A, Duijvesz D, Vásquez JL, Díez Sebastián J, Scarpa RM, Papalia R, Palou J, Gómez Rivas J. Interest and involvement of European urology residents in academic and research activities. An ESRU-ESU-ESUT collaborative study. Minerva Urol Nefrol. 2020 Jun;72(3):384-387. doi: 10.23736/S0393-2249.20.03734-0. Epub 2020 Mar 16. PMID: 32182232.

Ghayda RA, Carrion DM, Gomez Rivas J, Esperto F, Mantica G, Rodriguez-Socarras ME, Mattigk A, Kathrins M, O'Leary M, Niederberger C. Knowledge gap across continents: the andrology and male infertility exposure among urology residents in the United States and Europe. Int J Impot Res. 2020 Aug 21. doi: 10.1038/s41443-020-00342-2. Epub ahead of print. PMID: 32826968.

Mattigk A, Zengerling F. Nutzen der hypofraktionierten Strahlentherapie bei Männern mit lokalisiertem Prostatakarzinom [Effects of hypofractionated radiation therapy for men with localized prostate cancer]. Urologe A. 2020 Aug;59(8):953-956. German. doi: 10.1007/s00120-020-01262-1. PMID: 32666124.

Borgmann H, Struck JP, Mattigk A, Wenzel M, Pilatz A, Kranz J, Weiten R, von Landenberg N, Spachmann PJ, Aksoy C, Haferkamp A, Boehm K. Increased Severe Adverse Outcomes and Decreased Emergency Room Visits for Pyelonephritis: First Report of Collateral Damage during COVID-19 Pandemic in Urology. Urol Int. 2021 Jan 6:1-7. doi: 10.1159/000513458. Epub ahead of print. PMID: 33406523; PMCID: PMC7900463.

Dressler FF, Dogan S, Hennig M, Frank T, Struck J, Cebulla A, Salem J, Borgmann H, Klatte T, Kramer MW, Hofbauer S. Sicher zwischen Leitlinie und Leitplanke: Umfrage zur Praxis des perioperativen Managements der radikalen Zystektomie in Deutschland [Current practice patterns of perioperative cystectomy management in Germany: a questionnaire survey]. Aktuelle Urol. 2021 Feb;52(1):82-87. German. doi: 10.1055/a-1025-2523. Epub 2020 Jul 29. PMID: 32726815.

Wahby S, Jarczyk J, Fierek A, Heinkele J, Weis CA, Eckstein M, Martini T, Porubsky S, Hafner M, Erben P. POFUT1 mRNA expression as an independent prognostic parameter in muscle-invasive bladder cancer. Transl Oncol. 2021 Jan;14(1):100900. doi: 10.1016/j.tranon.2020.100900. Epub 2020 Oct 21. PMID: 33099185; PMCID: PMC7581975.

MK Melzer, F Wezel, M Breunig, J Krueger, J Merkle, M Hohwieler, C Guenes, A Kleger, C Bolenz. The potential for designing urothelial carcinomas using pluripotent stem cell-based systems. Urologic Oncology: Seminars and Original Investigations. 2020. 38 (12).909.

S Meessen, S Iben, A Azoitei, S Wiese, C Bolenz, C Günes. Oncology Research and Treatment 2020. 43, 2-2.

2019

Aydin AM, Singla N, Panwar V, Woldu SL, Freifeld Y, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Roscigno M, Bolenz C, Bensalah K, Westerman ME, Sagalowsky AI, Shariat SF, Lotan Y, Bagrodia A, Kapur P, Margulis V, Krabbe LM. Prognostic significance of BAP1 expression in high-grade upper tract urothelial carcinoma: a multi-institutional study. World J Urol. 2019 Nov;37(11):2419-2427. doi: 10.1007/s00345-019-02678-x. Epub 2019 Feb 13.

Bolenz C, Rother J, Meessen S, Grychtol B, Majlesara A, Gharabaghi N, Günes C, Ritter M, Deliolanis N, Michel MS, Kriegmair MC. [The development of real-time multispectral imaging for the diagnostics of bladder cancer]. Urologe A. 2019 Dec;58(12):1435-1442. doi: 10.1007/s00120-019-01037-3. Review. German.

Bolenz C, Hautmann RE. [Surgical treatment of bladder cancer: advances made in the past 50 years]. Aktuelle Urol. 2019 Aug;50(4):366-377. doi: 10.1055/a-0884-2792. Epub 2019 May 15. German.

Bolenz C, Michel MS, Struck JP. [Medical specialist training for urologists]. Urologe A. 2019 Feb;58(2):107-108. doi: 10.1007/s00120-019-0857-x. German. No abstract available.

Cebulla A, Bolenz C, Carrion DM, Bellut L. [Urology training in Germany: international comparison of educational concepts and satisfaction]. Urologe A. 2019 Feb;58(2):132-138. doi: 10.1007/s00120-019-0854-0. Review. German.

Cebulla A, Marx M, Struck JP. Opportunities and risks of a contemporary online presence for urologists. Aktuelle Urol. 2019 Aug;50(4):407-412. doi: 10.1055/a-0903-2299.

Dieckmann KP, Radtke A, Geczi L, Matthies C, Anheuser P, Eckardt U, Sommer J, Zengerling F, Trenti E, Pichler R, Belz H, Zastrow S, Winter A, Melchior S, Hammel J, Kranz J, Bolten M, Krege S, Haben B, Loidl W, Ruf CG, Heinzelbecker J, Heidenreich A, Cremers JF, Oing C, Hermanns T, Fankhauser CD, Gillessen S, Reichegger H, Cathomas R, Pichler M, Hentrich M, Eredics K, Lorch A, Wülfing C, Peine S, Wosniok W, Bokemeyer C, Belge G.

Serum Levels of MicroRNA-371a-3p (M371 Test) as a New Biomarker of Testicular Germ Cell Tumors: Results of a Prospective Multicentric Study. J Clin Oncol. 2019 Jun 1;37(16):1412-1423. doi: 10.1200/JCO.18.01480. Epub 2019 Mar 15.

Eckstein M, Erben P, Kriegmair MC, Worst TS, Weiß CA, Wirtz RM, Wach S, Stoehr R, Sikic D, Geppert CI, Weyerer V, Bertz S, Breyer J, Otto W, Keck B, Burger M, Taubert H, Weichert W, Wullich B, Bolenz C, Hartmann A, Erlmeier F. Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab. Eur J Cancer. 2019 Jan;106:234-243. doi: 10.1016/j.ejca.2018.11.007. Epub 2018 Dec 5.

Erben P, Sikic D, Wirtz RM, Martini T, Weis CA, Breyer J, Otto W, Keck B, Hartmann A, Bolenz C; BRIDGE Consortium e.V. Analysis of the prognostic relevance of sex-steroid hormonal receptor mRNA expression in muscle-invasive urothelial carcinoma of the urinary bladder. Virchows Arch. 2019 Feb;474(2):209-217. doi: 10.1007/s00428-018-2496-9. Epub 2018 Nov 27.

Ebert AK. [Bilateral reflux: contra "intravesical techniques"]. Aktuelle Urol. 2019 Dec 17. doi: 10.1055/a-0983-8240. [Epub ahead of print] German.

Ebert AK, Zwink N, Reutter HM. AUTHOR REPLY. Urology. 2019 Jan;123:219-220. doi: 10.1016/j.urology.2018.05.048.

Ebert AK, Zwink N, Jenetzky E, Stein R, Boemers TM, Lacher M, Fortmann C, Obermayr F, Fisch M, Mortazawi K, Schmiedeke E, Eisenschmidt V, Schäfer M, Hirsch K, Rösch WH, Reutter H.

Association Between Exstrophy-epispadias Complex And Congenital Anomalies: A German Multicenter Study. Urology. 2019 Jan;123:210-220. doi: 10.1016/j.urology.2018.05.039.

Foerster B, Shariat SF, Klein JT, Bolenz C. [Biopsy techniques in the upper urinary tract for the diagnosis of urothelial carcinoma: systematic review]. Urologe A. 2019 Jan;58(1):14-21. doi: 10.1007/s00120-018-0829-6. German.

Gahr M, Wezel F, Bolenz C, Connemann BJ, Schönfeldt-Lecuona C, Muche R, Fohrer C. Lithium Therapy Associated With Renal and Upper and Lower Urinary Tract Tumors: Results From a Retrospective Single-Center Analysis. J Clin Psychopharmacol. 2019 Sep/Oct;39(5):530-532. doi: 10.1097/JCP.0000000000001098. No abstract available.

Hautmann RE, Bolenz C, Volkmer B. Unexpected Early Oncologic Mortality after Open Radical Cystectomy for Bladder Cancer: Who Is to Be Blamed? Urol Int. 2019 Sep 27:1-6. doi: 10.1159/000503398. [Epub ahead of print]

Hechler V, Rink M, Beyersdorff D, Beer M, Beer AJ, Panebianco V, Pecoraro M, Bolenz C, Salomon G. [The role of the vesical imaging-reporting and data system (VI-RADS) for bladder cancer diagnostics-status quo]. Urologe A. 2019 Dec;58(12):1443-1450. doi: 10.1007/s00120-019-01061-3. Review. German.

Hupe MC, Hoda MR, Zengerling F, Perner S, Merseburger AS, Cronauer MV. The BET-inhibitor PFI-1 diminishes AR/AR-V7 signaling in prostate cancer cells. World J Urol. 2019 Feb;37(2):343-349. doi: 10.1007/s00345-018-2382-8. Epub 2018 Jun 22.

Klein JT, Berger F, Linzenbold W, Jäger L, Enderle MD, Bösmüller H, Mundhenk J, Schwentner C, Bolenz C. Cryobiopsy in the Upper Urinary Tract: Preclinical Evaluation of a Novel Device. Urology. 2019 Jan;123:273-279. doi: 10.1016/j.urology.2018.10.003. Epub 2018 Oct 9.

König J, Aeishen S, Cebulla A, Bellut L, Fassbach M, Westphal J, Struck JP. Quality instead of quantity improves medical education. Urologe A. 2019 Aug;58(8):877-880. doi: 10.1007/s00120-019-0987-1.

Kriegmair MC, Rother J, Grychtol B, Theuring M, Ritter M, Günes C, Michel MS, Deliolanis NC, Bolenz C. Multiparametric Cystoscopy for Detection of Bladder Cancer Using Real-time Multispectral Imaging. Eur Urol. 2019 Sep 26. pii: S0302-2838(19)30674-8. doi: 10.1016/j.eururo.2019.08.024. [Epub ahead of print]

Link C, Honeck P, Lohr F, Bolenz C, Schaefer J, Bohrer M, Giordano FA, Wenz F, Buergy D. Quality of Life and Decision Regret After Postoperative Radiation Therapy to the Prostatic Bed Region With or Without Elective Pelvic Nodal Radiation Therapy. Pract Radiat Oncol. 2019 Nov;9(6):e516-e527. doi: 10.1016/j.prro.2019.06.011. Epub 2019 Jun 27.

Link C, Honeck P, Makabe A, Giordano FA, Bolenz C, Schaefer J, Bohrer M, Lohr F, Wenz F, Buergy D. Postoperative elective pelvic nodal irradiation compared to prostate bed irradiation in locally advanced prostate cancer - a retrospective analysis of dose-escalated patients. Radiat Oncol. 2019 Jun 7;14(1):96. doi: 10.1186/s13014-019-1301-5.

Martini T, Heinkele J, Mayr R, Weis CA, Wezel F, Wahby S, Eckstein M, Schnöller T, Breyer J, Wirtz R, Ritter M, Bolenz C, Erben P. Erratum to 'Predictive value of lymphangiogenesis and proliferation markers on mRNA level in urothelial carcinoma of the bladder after radical cystectomy' [Urologic Oncology: Seminars and Original Investigations 36/12 (2018) 505-534]. Urol Oncol. 2019 Mar;37(3):227. doi: 10.1016/j.urolonc.2018.12.019. Epub 2018 Dec 27. No abstract available.

Morcos YAT, Najjar G, Meessen S, Witt B, Azoitei A, Kumar M, Wakileh G, Schwarz K, Schrezenmeier H, Zengerling F, Bolenz C, Günes C.A Novel Tissue and Stem Cell Specific TERF1 Splice Variant Is Downregulated in Tumour Cells. Int J Mol Sci. 2019 Dec 20;21(1). pii: E85. doi: 10.3390/ijms21010085.

Njeru SN, Kraus J, Meena JK, Lechel A, Katz SF, Kumar M, Knippschild U, Azoitei A, Wezel F, Bolenz C, Leithäuser F, Gollowitzer A, Omrani O, Hoischen C, Koeberle A, Kestler HA, Günes C, Rudolph KL. Aneuploidy-inducing gene knockdowns overlap with cancer mutations and identify Orp3 as a B-cell lymphoma suppressor. Oncogene. 2019 Oct 28. doi: 10.1038/s41388-019-1073-2. [Epub ahead of print]

Necknig U, Leyh H, Hauenstein K, Zwink N, Becker T, Ebert AK.

[Pilot study on drinking and voiding management in child day-care facilities in the district of Garmisch-Partenkirchen]. Urologe A. 2019 May;58(5):543-547. doi: 10.1007/s00120-018-0825-x. German.

Pfannstiel C, Strissel PL, Chiappinelli KB, Sikic D, Wach S, Wirtz RM, Wullweber A, Taubert H, Breyer J, Otto W, Worst T, Burger M, Wullich B, Bolenz C, Fuhrich N, Geppert CI, Weyerer V, Stoehr R, Bertz S, Keck B, Erlmeier F, Erben P, Hartmann A, Strick R, Eckstein M; BRIDGE Consortium, Germany; BRIDGE Consortium, Germany; BRIDGE Consortium, Germany; BRIDGE Consortium, Germany. The Tumor Immune Microenvironment Drives a Prognostic Relevance That Correlates with Bladder Cancer Subtypes. Cancer Immunol Res. 2019 Jun;7(6):923-938. doi: 10.1158/2326-6066.CIR-18-0758. Epub 2019 Apr 15.

Retz M, Bedke J, Bögemann M, Grimm MO, Zimmermann U, Müller L, Leiber C, Teber D, Wirth M, Bolenz C, van Alphen R, De Santis M, Beeker A, Lehmann J, Indorf M, Frank M, Bokemeyer C, Gschwend JE. SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11). Eur J Cancer. 2019 Jan;107:37-45. doi: 10.1016/j.ejca.2018.11.001. Epub 2018 Dec 7.

Salem J, Paffenholz P, Bolenz C, von Brandenstein M, Cebulla A, Haferkamp A, Kuru T, Lee CT, Pfister D, Tsaur I, Borgmann H, Heidenreich A. Websites on Bladder Cancer: an Appropriate Source of Patient Information? J Cancer Educ. 2019 Apr;34(2):381-387. doi: 10.1007/s13187-017-1316-2.

Sharma A, Fröhlich H, Zhang R, Ebert AK, Rösch W, Reis H, Kristiansen G, Ellinger J, Reutter H. Classic bladder exstrophy and adenocarcinoma of the bladder: Methylome analysis provide no evidence for underlying disease-mechanisms of this association. Cancer Genet. 2019 Jun;235-236:18-20. doi: 10.1016/j.cancergen.2019.05.004.

Sibert NT, Dieng S, Oesterle A, Feick G, Carl G, Steiner T, Minner J, Roghmann F, Kaftan B, Zengerling F, Hinkel A, Beyer B, Heidenreich A, Harke N, Brehmer B, Pfitzenmaier J, Fichtner J, Neisius A, Hammerer P, Wesselmann S, Kowalski C. Psychometric validation of the German version of the EPIC-26 questionnaire for patients with localized and locally advanced prostate cancer. World J Urol. 2019 Sep 24. doi: 10.1007/s00345-019-02949-7. [Epub ahead of print]

Sikic D, Wirtz RM, Wach S, Dyrskjøt L, Erben P, Bolenz C, Breyer J, Otto W, Hoadley KA, Lerner SP, Eckstein M, Hartmann A, Keck B. Androgen Receptor mRNA Expression in Urothelial Carcinoma of the Bladder: A Retrospective Analysis of Two Independent Cohorts. Transl Oncol. 2019 Apr;12(4):661-668. doi: 10.1016/j.tranon.2019.01.005. Epub 2019 Mar 2.

Sternberg CN, Loriot Y, James N, Choy E, Castellano D, Lopez-Rios F, Banna GL, De Giorgi U, Masini C, Bamias A, Garcia Del Muro X, Duran I, Powles T, Gamulin M, Zengerling F, Geczi L, Gedye C, de Ducla S, Fear S, Merseburger AS. Primary Results from SAUL, a Multinational Sngle-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract. Eur Urol. 2019 Jul;76(1):73-81. doi: 10.

Struck JP, Cebulla A, Ralla B, Koenig J. Structured training curriculum for urological residents: chances and limits. Urologe A. 2019 Feb;58(2):109-113. doi: 10.1007/s00120-018-0847-4.

Willbold R, Wirth K, Martini T, Sültmann H, Bolenz C, Wittig R. Excess hepsin proteolytic activity limits oncogenic signaling and induces ER stress and autophagy in prostate cancer cells. Cell Death Dis. 2019 Aug 9;10(8):601. doi: 10.1038/s41419-019-1830-8.

Yeh HC, Margulis V, Singla N, Hernandez E, Panwar V, Woldu SL, Karam JA, Wood CG, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Roscigno M, Bolenz C, Bensalah K, Li CC, Ke HL, Li WM, Lee HY, Rapoport LM, Lotan Y, Kapur P, Shariat SF, Hsieh JT, Wu WJ. PTRF independently predicts progression and survival in multiracial upper tract urothelial carcinoma following radical nephroureterectomy. Urol Oncol. 2019 Dec 17. pii: S1078-1439(19)30483-1. doi: 10.1016/j.urolonc.2019.11.010. [Epub ahead of print]

Zengerling F. [Phosphodiesterase inhibitors for the treatment of benign prostatic hyperplasia]. Urologe A. 2019 Sep;58(9):1084-1087. doi: 10.1007/s00120-019-1008-0. Review. German.

2018

Buergy D, Schneiberg V, Schaefer J, Welzel G, Trojan L, Bolenz C, Wenz F. Quality of life after low-dose rate-brachytherapy for prostate carcinoma - long-term results and literature review on QLQ-C30 and QLQ-PR25 results in published brachytherapy series. Health Qual Life Outcomes. 2018 Jan 22;16(1):21.

Bolenz C, Knauf D, John A, Erben P, Steidler A, Schneider SW, Günes C, Gorzelanny C. Decreased Invasion of Urothelial Carcinoma of the Bladder by Inhibition of Matrix-Metalloproteinase 7. Bladder Cancer. 2018 Jan 20;4(1):67-75.

Bolenz C, Schröppel B, Eisenhardt A, Schmitz-Dräger BJ, Grimm MO. The Investigation of Hematuria. Dtsch Arztebl Int. 2018 Nov 30;115(48):801-807. doi: 10.3238/arztebl.2018.0801.

Cebulla A, Bolenz C, Carrion DM, Bellut L. Urology training in Germany: international comparison of educational concepts and satisfaction. Urologe A. 2019 Jan 25. doi: 10.1007/s00120-019-0854-0.

Dogan S, Hennig M, Frank T, Struck JP, Cebulla A, Salem J, Borgmann H, Klatte T, Merseburger AS, Kramer M, Hofbauer SL. Acceptance of Adjuvant and Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer in Germany: A Survey of Current Practice. Urol Int. 2018;101(1): 25-30

Ebert AK, Zwink N, Schwarzer N, Brunner L, Reutter H, Jenetzky E, Huber J, Ludwikowski B. Needs Assessment in Care of Adults With Anorectal Malformations and Exstrophy-Epispadias Complex in Germany. Front Pediatr. 2018 Dec 19;6:392. doi: 10.3389/fped.2018.00392.

Ebert AK, Zwink N, Jenetzky E, Stein R, Boemers TM, Lacher M, Fortmann C, Obermayr F, Fisch M, Mortazawi K, Schmiedeke E, Eisenschmidt V, Schäfer M, Hirsch K, Rösch WH, Reutter H. Association Between Exstrophy-epispadias Complex And Congenital Anomalies: A German Multicenter Study. Urology. 2019 Jan;123:210-220. doi: 10.1016/j.urology.2018.05.039.

Ebert AK, Zwink N, Reutter HM. Urology. 2019 Jan;123:219-220. doi: 10.1016/j.urology.2018.05.048.

Eckstein M, Wirtz RM, Gross-Weege M, Breyer J, Otto W, Stoehr R, Sikic D, Keck B, Eidt S, Burger M, Bolenz C, Nitschke K, Porubsky S, Hartmann A, Erben P. mRNA-Expression of KRT5 and KRT20 Defines Distinct Prognostic Subgroups of Muscle-Invasive Urothelial Bladder Cancer Correlating with Histological Variants. Int J Mol Sci. 2018 Oct 30;19(11).

Eckstein M, Wirtz RM, Pfannstil C, Wach S, Stoehr R, Breyer J, Erlmeier F, Günes C, Nitschke K, Weichert W, Otto W, Keck B, Eidt S, Burger M, Taubert H, Wullich B, Bolenz C, Hartmann A, Erben P. A multicenter round robin test of PD-L1 expression assessment in urothelial bladder cancer by immunohistochemistry and RT-qPCR with emphasis on prognosis prediction after radical cystectomy. Oncotarget. 2018 Feb 19;9(19):15001-15014.

Eckstein M: Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab.

Günes C, Wezel F, Southgate J, Bolenz C. Implications of TERT promoter mutations and telomerase activity in urothelial carcinogenesis. Nat Rev Urol. 2018 Jun;15(6):386-393. doi: 10.1038/s41585-018-0001-5. Review.

Günes C, Avila AI, Rudolph KL. Telomeres in cancer. Differentiation. 2018 Jan - Feb;99:41-50. doi: 10.1016/j.diff.2017.12.004.

Hausmann D, Aksöz N, von Hardenberg J, Martini T, Westhoff N, Buettner S, Schoenberg SO, Riffel P. Prostate cancer detection among readers with different degree of experience using ultra-high b-value diffusion-weighted Imaging: Is a non-contrast protocol sufficient to detect significant cancer? Eur Radiol. 2018 Feb;28(2):869-876. doi: 10.1007/s00330-017-5004-8. Epub 2017 Aug 10.

Hautmann R, Bolenz C. Declining Use of Orthotopic Reconstruction for Bladder Cancer. Ann Surg Oncol. 2018 Nov;25(12):3421-3422. doi: 10.1245/s10434-018-6570-y.

Hupe MC, Hoda MR, Zengerling F, Perner S, Merseburger AS, Cronauer MV. The BET-inhibitor PFI-1 diminishes AR/AR-V7 signaling in prostate cancer cells. World J Urol. 2018 Jun 22. doi: 10.1007/s00345-018-2382-8. [Epub ahead of print]

Hustler A, Eardley I, Hinley J, Pearson J, Wezel F, Radvanyi F, Baker SC, Southgate J. Differential transcription factor expression by human epithelial cells of buccal and urothelial derivation. Exp Cell Res. 2018 Aug 15;369(2):284-294. doi: 10.1016/j.yexcr.2018.05.031.

John, A., Baumgart, A.,john a Worst, T., & Heinzelbecker, J. (2018). Economy of Standards: European Association of Urology Guideline Changes Influence Treatment Costs in Stage I Testicular Cancer Patients. Urologia internationalis, 100(3), 279-287.

John A, Gorzelanny C, Bauer AT, Schneider SW, Bolenz C. Role of the Coagulation System in Genitourinary Cancers. Clin Genitourin Cancer. 2017 Jul 26. pii: S1558-7673(17)30210-0. doi: 10.1016/j.clgc.2017.07.013.

Kriegmair MC, Honeck P, Theuring M, Bolenz C, Ritter M. Wide-field autofluorescence-guided TUR-B for the detection of bladder cancer: a pilot study. World J Urol. 2018 May;36(5):745-751.

Kriegmair MC, Wirtz RM, Worst TS, Breyer J, Ritter M, Keck B, Boehmer C, Otto W, Eckstein M, Weis CA, Hartmann A, Bolenz C, Erben P. Prognostic Value of Molecular Breast Cancer Subtypes based on Her2, ESR1, PGR and Ki67 mRNA-Expression in Muscle Invasive Bladder Cancer. Transl Oncol. 2018 Apr;11(2):467-476.

Martini T, Heinkele J, Mayr R, Weis CA, Wezel F, Wahby S, Eckstein M, Schnöller T, Breyer J, Wirtz R, Ritter M, Bolenz C, Erben P. Predictive value of lymphangiogenesis and proliferation markers on mRNA level in urothelial carcinoma of the bladder after radical cystectomy. Urol Oncol. 2018 Dec;36(12):530.e19-530.e27. doi: 10.1016/j.urolonc.2018.09.003.

Martinschek A, Welzel G, Ritter M, Heinrich E, Bolenz C, Trojan L. The concentration of console surgeons: prospective evaluation of the loss of attention in robotic-assisted procedures. J Robot Surg. 2018 Dec;12(4):673-678.

Mayr R, Gierth M, Zeman F, Reiffen M, Seeger P, Wezel F, Pycha A, Comploj E, Bonatti M, Ritter M, van Rhijn BWG, Burger M, Bolenz C, Fritsche HM, Martini T. Sarcopenia as a comorbidity-independent predictor of survival following radical cystectomy for bladder cancer. J Cachexia Sarcopenia Muscle. 2018 Jun;9(3):505-513.

Motzer et. Al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.N Engl J Med. 2018;378(14): 1277-1290.

Necknig U, Leyh H, Hauenstein K, Zwink N, Becker T, Ebert AK.[Pilot study on drinking and voiding management in child day-care facilities in the district of Garmisch-Partenkirchen]. Urologe A. 2018 Dec 12. doi: 10.1007/s00120-018-0825-x.

Rinaldetti S, Rempel E, Worst TS, Eckstein M, Steidler A, Weiss CA, Bolenz C, Hartmann A, Erben P. Subclassification, survival prediction and drug target analyses of chemotherapy-naïve muscle-invasive bladder cancer with a molecular screening. Oncotarget. 2018 May 25;9(40):25935-25945.

Singla N, Krabbe LM, Aydin AM, Panwar V, Woldu SL, Freifeld Y, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Roscigno M, Bolenz C, Bensalah K, Sagalowsky AI, Shariat SF, Lotan Y, Bagrodia A, Kapur P, Margulis V. Multi-institutional evaluation of the prognostic significance of EZH2 expression in high-grade upper tract urothelial carcinoma. Urol Oncol. 2018 Jul;36(7):343.e1-343.e8.

Traceviciute J, Zwink N, Jenetzky E, Reutter H, Hirsch K, Stein R, Rösch WH, Ebert AK. Sexual Function and Quality of Life in Adult Male Individuals with Exstrophy-Epispadias Complex-a Survey of the German CURE-Network. Urology. 2018 Feb;112:215-221. doi: 10.1016/j.urology.2017.08.063.

Vetterlein MW, Gild P, Kluth LA, Seisen T, Gierth M, Fritsche HM, Burger M, Protzel C, Hakenberg OW, von Landenberg N, Roghmann F, Noldus J, Nuhn P, Pycha A, Rink M, Chun FK, May M, Fisch M, Aziz A; PROMETRICS 2011 Study Group. Peri-operative allogeneic blood transfusion does not adversely affect oncological outcomes after radical cystectomy for urinary bladder cancer: a propensity score-weighted European multicentre study. BJU Int. 2018 Jan;121(1):101-110.

von Hardenberg J, Worst TS, Westhoff N, Erben P, Fuxius S, Müller M, Bolenz C, Weiss C, Heinrich E. Cell-Free DNA and Neuromediators in Detecting Aggressive Variant Prostate Cancer. Oncol Res Treat. 2018;41(10):627-633. doi: 10.1159/000490618.

von Hardenberg J, Westhoff N, Baumunk D, Hausmann D, Martini T, Marx A, Porubsky S, Schostak M, Michel MS, Ritter M. Prostate cancer treatment by the latest focal HIFU device with MRI/TRUS-fusion control biopsies: A prospective evaluation. Urol Oncol. 2018 Sep;36(9):401.e1-401.e9. doi: 10.1016/j.urolonc.2018.05.022.

Westhoff N, Siegel F, Peter C, Hetjens S, Porubsky S, Martini T, von Hardenberg J, Michel MS, Budjan J, Ritter M. Defining the target prior to prostate fusion biopsy: the effect of MRI reporting on cancer detection. World J Urol. 2018 Jul 2. doi: 10.1007/s00345-018-2400-x. [Epub ahead of print]

Wezel F, Erben P, Gaiser T, Budjan J, von Hardenberg J, Michel MS, Bolenz C. Complete and Durable Remission of Human Epidermal Growth Factor Receptor 2-Positive Metastatic Urothelial Carcinoma Following Third-Line Treatment with Trastuzumab and Gemcitabine. Urol Int. 2018;100(1):122-125. doi: 10.1159/000443280.

Worst TS, Weis CA, Stöhr R, Bertz S, Eckstein M, Otto W, Breyer J, Hartmann A, Bolenz C, Wirtz RM, Erben P. CDKN2A as transcriptomic marker for muscle-invasive bladder cancer risk stratification and therapy decision-making. Sci Rep. 2018 Sep 26;8(1):14383. doi: 10.1038/s41598-018-32569-x.

Zengerling F. Phytotherapy for benign prostatic hyperplasia. Urologe A. 2018 Jun 6. doi: 10.1007/s00120-018-0687-2.

Zengerling F, Kunath F, Jensen K, Ruf C, Schmidt S, Spek A. Prognostic factors for tumor recurrence in patients with clinical stage I seminoma undergoing surveillance-A systematic review. Urol Oncol. 2018 Oct;36(10):448-458. doi: 10.1016/j.urolonc.2017.06.047.

Zuiverloon TCM, van Kessel KEM, Bivalacqua TJ, Boormans JL, Ecke TH, Grivas PD, Kiltie AE, Liedberg F, Necchi A, van Rhijn BW, Roghmann F, Sanchez-Carbayo M, Schmitz-Dräger BJ, Wezel F, Kamat AM. Recommendations for follow-up of muscle-invasive bladder cancer patients: A consensus by the international bladder cancer network. Urol Oncol. 2018 Sep;36(9):423-431. doi: 10.1016/j.urolonc.2018.01.014. Review.

2017

Beck A, Cebulla A, Salem J, Struck JP, Borgmann H. Twitter activity at the German Society of Urology congress #DGU16. Urologe A. 2017 Jan;56(1):77-79. doi: 10.1007/s00120-016-0285-0. German. PubMed PMID: 27921125.

Blasl F, Rösch WH, Koen M, Ardelean MA, Ebert AK. Cowper's syringocele: A rare differential diagnosis of infravesical obstruction in boys and young adults. J Pediatr Urol. 2017 Feb;13(1):52.e1-52.e5. doi: 10.1016/j.jpurol.2016.08.023. Epub 2016 Oct 8.

Bottke D, Bolenz C, Ott S, Cebulla A, Wiegel T. When should the primary tumor of metastatic bladder or prostate cancer be treated using a nonsurgical regimen?. Urologe A. 2017 May;56(5):579-584. doi: 10.1007/s00120-017-0356-x. German. PubMed PMID: 28349190.

Ebert AK. Acute Flank Pain in Children and Adolescents. Aktuelle Urol. 2017 Sep;48(5):452-458. doi: 10.1055/s-0043-103501. Epub 2017 Sep 5. German.

Ebert AK, Stehr M. Phimosis in a 10-yr-old Boy Without Urinary Infection-How to Inform Parents: Against Circumcision. Eur Urol Focus. 2017 Apr;3(2-3):151-152. doi: 10.1016/j.euf.2017.06.006. Epub 2017 Jun 20.

Ebert AK. The German research network CURE-Net : A benefit for patients with rare diseases]. Urologe A. 2017 Jul;56(7):905-909. doi: 10.1007/s00120-017-0403-7. Review. German.

Ebert AK, Lange T, Reutter H, Jenetzky E, Stein R, Boemers TM, Hirsch K, Rösch WH, Zwink N. Evaluation of sexual function in females with exstrophy-epispadias-complex: A survey of the multicenter German CURE-Net. J Pediatr Urol. 2017 Apr;13(2):183.e1-183.e6. doi: 10.1016/j.jpurol.2016.04.052. Epub 2016 Jul 13.

Erben P, Wezel F, Wirtz R, Martini T, Stein D, Weis CA, Hartmann A, Bolenz C. [Role of the human ErbB family receptors in urothelial carcinoma of the bladder: mRNA expression status and prognostic relevance]. Aktuelle Urol. 2017 Aug;48(4):356-362. doi: 10.1055/s-0043-110403. Epub 2017 Jul 27. German.

Gunes C, Avila AI, Rudolph KL. Telomeres in cancer. Differentiation. 2017 Dec 21;99:41-50. doi: 10.1016/j.diff.2017.12.004. [Epub ahead of print] Review. PMID: 29291448

Hofbauer S, Kalogirou C, Roghmann F, Seitz AK, Vallo S, Wezel F, Worst T, Nawroth R. Modern networks : Topics in the working group "Bladder cancer research" of the GeSRU Academics. Urologe A. 2017 Feb;56(2):202-207. doi: 10.1007/s00120-016-0217-z. Review. German. PubMed PMID: 27604705.

John A, Gorzelanny C, Bauer AT, Schneider SW, Bolenz C. Role of the Coagulation System in Genitourinary Cancers: Review. Clin Genitourin Cancer. 2017 Jul 26. pii: S1558-7673(17)30210-0. doi: 10.1016/j.clgc.2017.07.013. [Epub ahead of print] Review.

Krabbe LM, Heitplatz B, Preuss S, Hutchinson RC, Woldu SL, Singla N, Boegemann M, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Rapoport LM, Glybochko PV, Roscigno M, Bolenz C, Bensalah K, Sagalowsky AI, Shariat SF, Lotan Y, Xylinas E, Margulis V. Prognostic Value of PD-1 and PD-L1 Expression in Patients with High Grade Upper Tract Urothelial Carcinoma. J Urol. 2017 Dec;198(6):1253-1262. doi: 10.1016/j.juro.2017.06.086. Epub 2017 Jun 28.

Kriegmair MC, Ritter M, Michel MS, Bolenz C. Modern endoscopic imaging tools for urothelial carcinoma of the urinary bladder. Aktuelle Urol. 2017 Aug;48(4):296-305. doi: 10.1055/s-0043-109820. Epub 2017 Jul 27. German.

Kriegmair MC, Honeck P, Theuring M, Bolenz C, Ritter M. Wide-field autofluorescence-guided TUR-B for the detection of bladder cancer: a pilot study. World J Urol. 2017 Dec 6. doi: 10.1007/s00345-017-2147-9. [Epub ahead of print]

Kriegmair MC, Bergen T, Ritter M, Mandel P, Michel MS, Wittenberg T, Bolenz C. Digital Mapping of the Urinary Bladder: Potential for Standardized Cystoscopy Reports. Urology. 2017 Jun;104:235-241. doi: 10.1016/j.urology.2017.02.019. Epub 2017 Feb 16.

Martini T, Gilfrich C, Mayr R, Burger M, Pycha A, Aziz A, Gierth M, Stief CG, Müller SC, Wagenlehner F, Roigas J, Hakenberg OW, Roghmann F, Nuhn P, Wirth M, Novotny V, Hadaschik B, Grimm MO, Schramek P, Haferkamp A, Colleselli D, Kloss B, Herrmann E, Fisch M, May M, Bolenz C. The Use of Neoadjuvant Chemotherapy in Patients With Urothelial Carcinoma of the Bladder: Current Practice Among Clinicians. Clin Genitourin Cancer. 2017 Jun;15(3):356-362. doi: 10.1016/j.clgc.2016.09.003. Epub 2016 Sep 19. PMID: 27765613

Martini T, Wezel F, Löbig N, Mitterberger MJ, Colleselli D. [Systematic review on conservative treatment options in non-muscle-invasive bladder cancer patients refractory to Bacillus Calmette-Guérin instillation therapy]. Aktuelle Urol. 2017 Aug;48(4):314-328. doi: 10.1055/s-0043-108944. Epub 2017 Jun 13. German. PMID: 28609792

Martinschek A, Stumm L, Ritter M, Heinrich E, Bolenz C, Trojan L. Prospective, Controlled Study of Invasiveness and Post-Aggression Metabolism in Patients Undergoing Robotic-Assisted Radical Prostatectomy. Urol Int. 2017;99(2):201-206. doi: 10.1159/000478027. Epub 2017 Jul 29.

May M, Protzel C, Vetterlein MW, Gierth M, Noldus J, Karl A, Grimm T, Wullich B, Grimm MO, Nuhn P, Bastian PJ, Roigas J, Hadaschik B, Gilfrich C, Burger M, Fisch M, Brookman-May S, Aziz A, Hakenberg OW; PROMETRICS 2011 Research Group. Is there evidence for a close connection between side of intravesical tumor location and ipsilateral lymphatic spread in lymph node-positive bladder cancer patients at radical cystectomy? Results of the PROMETRICS 2011 database. Int Urol Nephrol. 2017 Feb;49(2):247-254. doi: 10.1007/s11255-016-1469-7. Epub 2016 Nov 28.

Ralla B, Arnold H, König J, Cebulla A, Nestler T, Struck J, Borgmann H, Salem J. Relaunch of the GeSRU website : Strategy, concept, and realization. Urologe A. 2017 Apr;56(4):512-514. doi: 10.1007/s00120-017-0367-7. German. PubMed PMID:28293704.

Reutter H, Hirsch K, Stein R, Rösch WH, Ebert AK. Sexual Function and Quality of Life in Adult Male Individuals with Exstrophy-Epispadias Complex - a Survey of the German CURE-Network. Traceviciute J, Zwink N, Jenetzky E, Urology. 2017 Nov 7. pii: S0090-4295(17)31160-3. doi: 10.1016/j.urology.2017.08.063. [Epub ahead of print]

Rinaldetti S, Wirtz RM, Worst TS, Eckstein M, Weiss CA, Breyer J, Otto W, Bolenz C, Hartmann A, Erben P. FOXM1 predicts overall and disease specific survival in muscle-invasive urothelial carcinoma and presents a differential expression between bladder cancer subtypes. Oncotarget. 2017 Jul 18;8(29):47595-47606. doi: 10.18632/oncotarget.17394.

Struck JP, Paffenholz P, Nachite S, Cebulla A, Ralla B, Salem J. GeSRU e. V. - a success story. Urologe A. 2017 Feb;56(2):245-246. doi:10.1007/s00120-016-0306-z. German. PubMed PMID: 28093612.

Vallo S, Rutz J, Kautsch M, Winkelmann R, Michaelis M, Wezel F, Bartsch G, Haferkamp A, Rothweiler F, Blaheta RA, Cinatl Jr J Jr. Blocking integrin β1 decreases adhesion in chemoresistant urothelial cancer cell lines. Oncol Lett. 2017 Nov;14(5):5513-5518. doi: 10.3892/ol.2017.6883. Epub 2017 Sep 4. PubMed PMID: 29113179; PubMed Central PMCID: PMC5661377.

Vallo S, Köpp R, Michaelis M, Rothweiler F, Bartsch G, Brandt MP, Gust KM, Wezel F, Blaheta RA, Haferkamp A, Cinatl J Jr. Resistance to nanoparticle albumin-bound paclitaxel is mediated by ABCB1 in urothelial cancer cells. Oncol Lett. 2017 Jun;13(6):4085-4092. doi: 10.3892/ol.2017.5986. Epub 2017 Apr 5. PubMed PMID: 28599410; PubMed Central PMCID: PMC5453046.

Vetterlein MW, Meyer CP, Leyh-Bannurah SR, Mayr R, Gierth M, Fritsche HM, Burger M, Keck B, Wullich B, Martini T, Bolenz C, Pycha A, Hanske J, Roghmann F, Noldus J, Bastian PJ, Gilfrich C, May M, Rink M, Chun FK, Dahlem R, Fisch M, Aziz A; Effect of Hospital and Surgeon Case Volume on Perioperative Quality of Care and Short-term Outcomes After Radical Cystectomy for Muscle-invasive Bladder Cancer: Results From a European Tertiary Care Center Cohort. PROMETRICS 2011 study group. Clin Genitourin Cancer. 2017 Oct;15(5):e809-e817. doi: 10.1016/j.clgc.2017.04.021. Epub 2017 Apr 26. PMID: 28550955

VON Hardenberg J, Schwartz M, Werner T, Fuxius S, Müller M, Frangenheim T, Bolenz C, Weiss C, Heinrich E. Prospective Evaluation of Neuromediator Dynamics in Castration-Resistant Prostate Cancer Patients During Docetaxel. Anticancer Res. 2017 Sep;37(9):5117-5124.

von Hardenberg J, Schwartz M, Werner T, Fuxius S, Strauss A, Worst TS, Nuhn P, Bolenz C, Heinrich E. Oncologic Response and Hospitalization Rate of Patients Receiving Cabazitaxel in the Fourth-Line and Beyond in Castration-Resistant Prostate Cancer: Analysis of a Retrospective Cohort and a Structured Literature Review. Urol Int. 2017;99(4):414-421. doi: 10.1159/000477943. Epub 2017 Jul 13.

K Walter, M Ventura Ferreira, V Usachov, S Alcala, C Günes, T Seufferlein, B Sainz Anding, A Kleger, F Beier, P Hermann. Telomeraseinhibition führt zur Elimination von tumor-initiierenden Zellen im humanen Pankreaskarzinom. Zeitschrift für Gastroenterologie

Weber R, Cebulla A, Nachite-Berges S, Paffenholz P, Salem J, Ralla B, Uhthoff H, Schröder A, Struck JP. [Upgrade of the resident's job exchange platform]. Urologe A. 2017 Oct;56(10):1333-1334. doi: 10.1007/s00120-017-0502-5. German. PubMed PMID: 28900656.

Wundrack FM, Paffenholz P, Probst K, Sanatgar N, Cebulla A, Nestler T, Struck J, Nachite-Berges S, Salem J, Ralla B. [GeSRU programs at regional urology meetings in Germany 2017]. Urologe A. 2017 Jun;56(6):804-805. doi: 10.1007/s00120-017-0411-7. German. PubMed PMID: 28508940.

Zhang R, Knapp M, Suzuki K, Kajioka D, Schmidt JM, Winkler J, Yilmaz Ö, Pleschka M, Cao J, Kockum CC, Barker G, Holmdahl G, Beaman G, Keene D, Woolf AS, Cervellione RM, Cheng W, Wilkins S, Gearhart JP, Sirchia F, Di Grazia M, Ebert AK, Rösch W, Ellinger J, Jenetzky E, Zwink N, Feitz WF, Marcelis C, Schumacher J, Martinón-Torres F, Hibberd ML, Khor CC, Heilmann-Heimbach S, Barth S, Boyadjiev SA, Brusco A, Ludwig M, Newman W, Nordenskjöld A, Yamada G, Odermatt B, Reutter H. ISL1 is a major susceptibility gene for classic bladder exstrophy and a regulator of urinary tract development. Sci Rep. 2017 Feb 8;7:42170. doi: 10.1038/srep42170.

2016

Azoitei A, Merseburger AS, Godau B, Hoda MR, Schmid E, Cronauer MV. C-terminally truncated constitutively active androgen receptor variants and their biologic and clinical significance in castration-resistant prostate cancer. J Steroid Biochem Mol Biol. 2017 Feb;166:38-44. doi: 10.1016/j.jsbmb.2016.06.008.

Blasl F, Rösch WH, Koen M, Ardelean MA, Ebert AK. Cowper's syringocele: A rare differential diagnosis of infravesical obstruction in boys and young adults. J Pediatr Urol. 2016 Oct 8. pii: S1477-5131(16)30287-X. doi: 10.1016/j.jpurol.2016.08.023. [Epub ahead of print]

Bottke D, Bartkowiak D, Bolenz C, Wiegel T. [Radiotherapy in node-positive prostate cancer]. Urologe A. 2016 Mar;55(3):345-9. doi: 10.1007/s00120-016-0044-2. Review. German.

Breunig C, Zengerling F, Schnöller T, Schrader M, Jentzmik F. Recent Therapy of Organ-confined Testis Cancer. Aktuelle Urol. 2016 Apr;47(2):136-40. doi: 10.1055/s-0041-103446.

Busch J, Seidel C, Zengerling F. Male Extragonadal Germ Cell Tumors of the Adult. Oncol Res Treat. 2016;39(3):140-4. doi: 10.1159/000444271.

Cindric V.A., Reiche J., Hoischen C., Wohlmann A., Bratsch J., Friedrich K., Günes B., Cappallo-Obermann H., Kirchhoff C., Diekmann S., Günes C., Huber O. Characterization of SKAP/kinastrin isoforms: the N-terminus defines tissue specificity and Pontin binding. Hum Mol Genet. 2016 May 11.

Ebert AK. Editorial Comment. J Urol. 2016 Feb;195(2):470; discussion 470. doi: 10.1016/j.juro.2015.08.107. No abstract available.

Ebert AK, Lange T, Reutter H, Jenetzky E, Stein R, Boemers TM, Hirsch K, Rösch WH, Zwink N. Evaluation of sexual function in females with exstrophy-epispadias-complex: A survey of the multicenter German CURE-Net. J Pediatr Urol. 2016 Jul 13. pii: S1477-5131(16)30149-8. doi: 10.1016/j.jpurol.2016.04.052. [Epub ahead of print]

Hofbauer S, Kalogirou C, Roghmann F, Seitz AK, Vallo S, Wezel F, Worst T, Nawroth R. [Modern networks : Topics in the working group "Bladder cancer research" of the GeSRU Academics]. Urologe A. 2016 Sep 7. [Epub ahead of print] German

Jentzmik F, Azoitei A, Zengerling F, Damjanoski I, Cronauer MV. Androgen receptor aberrations in the era of abiraterone and enzalutamide. World J Urol. 2016 Mar;34(3):297-303. doi: 10.1007/s00345-015-1624-2.

Kertai MA, Rösch WH, Brandl R, Hirschfelder H, Zwink N, Ebert AK. Morphological and Functional Hip Long-Term Results after Exstrophy Repair. Eur J Pediatr Surg. 2016 Dec;26(6):508-513.

Krabbe LM, Eminaga O, Shariat SF, Hutchinson RC, Lotan Y, Sagalowsky AI, Raman JD, Wood CG, Weizer AZ, Roscigno M, Montorsi F, Bolenz C, Novara G, Kikuchi E, Fajkovic H, Rapoport LM, Glybochko PV, Zigeuner R, Remzi M, Bensalah K, Kassouf W, Margulis V. Postoperative Nomogram for Relapse-Free Survival in Patients with High Grade Upper Tract Urothelial Carcinoma. J Urol. 2016 Sep 23. pii: S0022-5347(16)31376-3. doi: 10.1016/j.juro.2016.09.078. [Epub ahead of print]

Kriegmair MC, Balk M, Wirtz R, Steidler A, Weis CA, Breyer J, Hartmann A, Bolenz C, Erben P. Expression of the p53 Inhibitors MDM2 and MDM4 as Outcome Predictor in Muscle-invasive Bladder Cancer. Anticancer Res. 2016 Oct;36(10):5205-5213.

Kriegmair MC, Mandel P, Moses A, Bolenz C, Michel MS, Pfalzgraf D. Zonal NephRo Score: external validation for predicting complications after open partial nephrectomy. World J Urol. 2016 Apr;34(4):545-51. doi: 10.1007/s00345-015-1648-7.

Kumar, M., Lechel, A., Günes C. Telomerase: The Devil Inside. Genes 7 (8), 2016 Jul 29;7(8).

Kunath F, Spek A, Jensen K, Zengerling F, Schmidt S. Prognostic factors for tumor recurrence in patients with clinical stage I seminoma undergoing surveillance--protocol for a systematic review. Syst Rev. 2015 Dec 18;4:182. doi: 10.1186/s13643-015-0167-3.

Martini T, Aziz A, Roghmann F, Rink M, Chun FK, Fisch M, Trojan L, Hakenberg OW, Zastrow S, Wirth MP, Moersdorf J, Brookman-May S, Stief CG, Haferkamp A, Wagenlehner F, Hohenfellner M, Herrmann E, Lusuardi L, Grimm MO, Müller SC, Roigas J, Bastian PJ, Gierth M, Burger M, Pycha A, Seitz C, May M, Bolenz C. Prediction of Locally Advanced Urothelial Carcinoma of the Bladder Using Clinical Parameters before Radical Cystectomy--A Prospective Multicenter Study. Urol Int. 2016;96(1):57-64. doi: 10.1159/000433606.

Martini T, Gilfrich C, Mayr R, Burger M, Pycha A, Aziz A, Gierth M, Stief CG, Müller SC, Wagenlehner F, Roigas J, Hakenberg OW, Roghmann F, Nuhn P, Wirth M, Novotny V, Hadaschik B, Grimm MO, Schramek P, Haferkamp A, Colleselli D, Kloss B, Herrmann E, Fisch M, May M, Bolenz C. The Use of Neoadjuvant Chemotherapy in Patients With Urothelial Carcinoma of the Bladder: Current Practice Among Clinicians. Clin Genitourin Cancer. 2016 Sep 19. pii: S1558-7673(16)30276-2. doi: 10.1016/j.clgc.2016.09.003. [Epub ahead of print]

May M, Fritsche HM, Vetterlein MW, Bastian PJ, Gierth M, Nuhn P, Aziz A, Fisch M, Stief CG, Hohenfellner M, Wirth MP, Novotny V, Hakenberg OW, Noldus J, Gilfrich C, Bolenz C, Burger M, Brookman-May SD; PROMETRICS 2011 Research Group. Impact of photodynamic diagnosis-assisted transurethral resection of bladder tumors on the prognostic outcome after radical cystectomy: results from PROMETRICS 2011. World J Urol. 2016 Jun 14. [Epub ahead of print]

Mbeutcha A, Lucca I, Margulis V, Karam JA, Wood CG, de Martino M, Mathieu R, Haitel A, Xylinas E, Kluth L, Rouprêt M, Karakiewicz PI, Briganti A, Rink M, Rieken M, Weizer AZ, Raman JD, Rioux-Leclecq N, Bolenz C, Bensalah K, Lotan Y, Seitz C, Remzi M, Shariat SF, Klatte T. Prognostic role of ERCC1 protein expression in upper tract urothelial carcinoma following radical nephroureterectomy with curative intent. World J Urol. 2016 Aug;34(8):1155-61. doi: 10.1007/s00345-015-1737-7.

Raman JD, Warrick JI, Caruso C, Yang Z, Shuman L, Bruggeman RD, Shariat S, Karam JA, Wood C, Weizer AZ, Remzi M, Haitel A, Bensalah K, Rioux-Leclerq N, Bolenz C, Roscigno M, Krabbe LM, Kapur P, Lotan Y, Margulis V, DeGraff DJ. Altered Expression of the Transcription Factor Forkhead Box A1 (FOXA1) Is Associated With Poor Prognosis in Urothelial Carcinoma of the Upper Urinary Tract. Urology. 2016 Aug;94:314.e1-7. doi: 10.1016/j.urology.2016.05.030.

Schrader M, Zengerling F, Hakenberg OW, Protzel C. German national second-opinion network for testicular cancer and penile carcinoma : Two sources for evidence-based information. Urologe A. 2016 Sep;55(9):1192-8. doi: 10.1007/s00120-016-0201-7.

Vallo S, Michaelis M, Gust KM, Black PC, Rothweiler F, Kvasnicka HM, Blaheta RA, Brandt MP, Wezel F, Haferkamp A, Cinatl J Jr. Dasatinib enhances tumor growth in gemcitabine-resistant orthotopic bladder cancer xenografts. BMC Res Notes. 2016 Sep 27;9(1):454.

von Hardenberg J, Schwartz M, Werner T, Fuxius S, Müller M, Bolenz C, Weiß C, Heinrich E. Influence of abiraterone acetate on circulating neuromediators in chemotherapy-naïve castration-resistant prostate cancer. Prostate. 2016 May;76(7):613-9. doi: 10.1002/pros.23152.

von Lowtzow C, Hofmann A, Zhang R, Marsch F, Ebert AK, Rösch W, Stein R, Boemers TM, Hirsch K, Marcelis C, Feitz WF, Brusco A, Migone N, Di Grazia M, Moebus S, Nöthen MM, Reutter H, Ludwig M, Draaken M. CNV analysis in 169 patients with bladder exstrophy-epispadias complex. BMC Med Genet. 2016 Apr 30;17(1):35. doi: 10.1186/s12881-016-0299-x.

Zengerling F, Schmidt S. Antioxidants for male subfertility. Urologe A. 2016 Jul;55(7):956-9. doi: 10.1007/s00120-016-0146-x.

Zengerling F, Azoitei A, Herweg A, Jentzmik F, Cronauer MV. Inhibition of IGF-1R diminishes transcriptional activity of the androgen receptor and its constitutively active, C-terminally truncated counterparts Q640X and AR-V7. World J Urol. 2016 May;34(5):633-9. doi: 10.1007/s00345-015-1674-5.

Die Ulmer Universitätsmedizin bietet Ihnen fächerübergreifende universitäre Spitzenmedizin, die Krankenversorgung, Forschung und Lehre verbindet.

Bessere Medizin durch Forschung Das Universitätsklinikum Ulm steht für Spitzenforschung mit Forschungsschwerpunkten in verschiedenen Fachgebiete.

Klinische Studien finden

Publikationen

2021